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Abstract
Over 170 million people worldwide are infected with hepatitis C virus (HCV) The 
immune system is effective at clearing the virus in a small proportion o f infected 
individuals while most people become persistently infected with the virus and develop 
chronic liver disease. Natural killer (NK) cells are thought to mediate immunity against 
viruses. They can lyse virus infected cells and release anti-viral cytokines. The roles o f  
NK cells and natural killer receptor positive (NKR+) T cells in immunity agamst HCV 
is largely unknown. The aim o f  the present study was to investigate the hypothesis that 
NK cells and NKR+ T cells numbers and/or functions are depleted in patients with 
chronic HCV infection. Flow cytometry was used to evaluate the numbers and 
phenotypes o f NK cell and NKR+ T cells in peripheral blood o f 33 patients with 
chrome HCV infection, 22 patients who spontaneously resolved HCV infection and 26 
healthy controls. Natural cytotoxicity and interleukin-2-activated killing o f  K562 and 
Daudi cells by peripheral blood mononuclear cells (PBMCs) were assessed using 
5'chromium release assays. NK cells and NKR+ T cells were depleted in patients with 
chronic HCV compared to the healthy controls (3.4% vs 13.7% for NK cells; p<0.001 
and 1.3% vs 3.7% for CD56+ T cells; p=0.0001). NK cells and CD56+ T cells were also 
depleted in HCV resolvers compared to controls. The frequencies o f expression o f  
CD16, CD56, CD161, KIR2DL1 and KIR3DL1/S1 by T and non-T cells were also 
altered in chronic HCV patients compared to controls. Natural cytotoxicity by PBMCs 
against K562 cells was impaired in patients with chronic HCV infection compared with 
controls (mean specific lysis at effector/target ratios o f  50:1 were 1.8% vs 10.2%; 
p<0.001) and HCV resolvers (7.4%, p=0.0012). IL-2 induced cytotoxicity against K562 
and Daudi targets was also impaired in patients with chronic HCV disease compared to
3
HCV resolvers and controls (2.4% vs 7.6% and 12.6% respectively, p<0.001 for K562 
and 0% vs 2.5% and 8.1%; p<0.001 for Daudi). Spearman analysis indicated that the 
impaired cytotoxic activity and L AK activity in the patients is not solely due to 
decreased NK or NKR+ T cell numbers. This study suggests that altered NK levels and 
activities are associated with HCV infection and may be responsible, at least in part, for 
the chronicity o f the infection
4
CONTENTS
Dedication 2
Abstract 3
Contents 5
List o f Tables 9
List o f Figuers 10
Acknowledgements 12
Declaration 13
Abbreviations 14
Chapter 1. Introduction
1.1A  brief introduction to the immune system 19
1.1.1 The innate immune system 19
1.1.2 Adaptive immunity 22
1.1.3 Hepatic lymphocyte repertoires 26
1 2 Natural killer cells 27
1.2.1 Role o f  NK cells in immune responses 28
1.2.2 Mechanisms o f NK cytotoxicity 29
1.2 2 1 Perforin/ granzyme granules 30
1.2.2.2 Fas/ Fas ligand 31
1.2.3 NK cell receptors 31
1.2.3.1 Human activating receptors 33
Title 1
5
1.2.3.2 Costimulatory receptors 36
1.2.3.3 Inhibitory receptors 36
1.2.3 4 Stimulatory/Inhibitory receptors 37
1.3 Natural killer receptors positive T cells (NKR+ T cells) 41
1.4 Natural killer T cells (NKT cells) 44
1.5 Hepatitis C 47
1.5 1 Hepatitis C virus (HCV) 47
1.5.2 HCV disease 49
1.5.3 Diagnosis o f hepatitis C 51
1.5.4 Treatment o f hepatitis C 51
1.5.5 Host immune response to HCV 53
1 5.6 Quasispecies 54
1 5.7 Role o f  antibodies m immunity agamst HCV 56
1.5.8 Role o f  T cells in immunity agamst HCV 57
1.5.9 Role o f dendritic cells in immunity against HCV 60
1.5.10 Role ofN K  cell in immunity against HCV 61
1.6 Aims o f the project 63 
Chapter 2: Materials and Methods
2.1 Subjects 65
2 2 Materials 66
2.2.1 General reagents 66
2.2.2 Antibodies 66
2.2.3 Cell lmes 67
6
2.3 Preparation o f peripheral blood mononuclear cells (PBMCs) 67
2.4 Enumeration o f PBMCs 68
2.5 Cryopreservation o f cells 69
2.6 Phenotypic analysis by flow cytometry 69
2.6.1 Brief background to flow cytometry 69
2 6.2 Monoclonal antibody (mAb) staining o f  PBMCs 71
2.6.3 Flow cytometric acquisition and analysis o f  data 72
2.7 Cell culture 72
2.8 Analysis o f cytotoxicity 74
2.9 Statistical analyses 77
Chapter 3: Results
3.1 A variety o f  NKRs are expressed by human T cells and non-T lymphocytes 79
3.2 Circulating NK cell numbers are depleted in patients with chronic HCV 
disease 79
3.3 Circulating NKR+ T cell numbers are depleted in patients with chronic HCV 
disease 82
3.4 NK cell phenotypes in patients and controls 82
3.5 NKR+ T cell phenotypes in patients and controls 85
3.6 Natural cytotoxicity by PBMCs is impaired in patients with chronic HCV 
infection 87
3.7 Lymphokine-activated killing (LAK) by PBMCs is impaired in patients
with chronic HCV infection 91
2.2.4 Plasticware 67
7
3.8 Impaired cytotoxic activity o f  PBMCs m chronic HCV infection is not
solely due to decreased NK cell numbers or NKR+ T cells numbers 91
Chapter 4: Discussion 96
References 104
8
LIST OF TABLES
1 NK cells activating receptors and their ligands
2 Monoclonal antibody staining o f PBMCs
1 Recognition o f danger by the innate immune system 21
2 Distribution o f lymphocyte subpopulations in healthy human blood
and liver 27
3 Cytokine mediated pathways and responses in NK cells 30
4 NK cells function through a repertoire o f  activating and inhibitory
Receptors 33
5 NK cell stimulatory and inhibitory receptors 38
6 KIR receptors and their domains 39
7 Natural killer receptor positive (NKR+) T cells initiate and regulate
innate and adaptive immune responses in the human 43
8 CD Id molecules present lipid antigens to NKT cells 45
9 Organisation o f the HCV genome 48
10 Players in the immune response against HCV and their roles 53
11 HCV evolves strategies to evade and modulate immune responses 55
12 Setting up the flow cytometer for 3-colour analysis o f  lymphocytes 73
13 Flow cytometric analysis o f  CD16, CD56, CD161, KIR2DL1 and
KIR3DL1/S1 by T cells (CD3+) and non-T lymphocytes (CD3‘) in the 
peripheral blood o f a healthy individual after gating on lymphocytes 80
14 Circulating NK cell numbers are depleted in chronic HCV disease 81
15 Circulating NKR+ T cells numbers are depleted in chronic HCV disease 83
16 Expression o f CD16, CD56, CD161, KIR2DL1 and KIR3DL1/S1 by 
circulating CD3' lymphocytes in healthy controls, patients with
chrome HCV disease and HCV resolvers 84
LIST OF FIGURES
10
17 Expression o f CD16, CD56, CD161, KIR2DL1 and KIR3DL1/S1 by 
circulating CD3+ lymphocytes in healthy controls, patients with
chronic HCV disease and HCV resolvers 86
18 Natural cytotoxicity against K562 targets is impaired m chronic
HCV infection 88
19 Natural cytotoxicity against Daudi targets is impaired in chronic
HCV infection 89
20 Natural cytotoxicity o f Daudi targets does not correlate with NK
cell phenotype 90
21 Lymphokine activated killing o f K562 target is impaired m chronic
HCV infection 93
22 Lymphokine activated killing o f  Daudi target is impaired in chrome
HCV infection 94
23 Reduced natural cytotoxicity and LAK activity in chronic HCV disease
is not solely due to depletion o f NK cell numbers 95
24 Reduced natural cytotoxicity and LAK activity in chronic HCV disease
is not solely due to depletions o f total NK or NKR+ T cell numbers 95
11
ACKNOWLEDGEMENTS
I am indebted to my supervisor Dr. Derek Doherty for his helpful comments and 
suggestions and for his encouragement.
I am also grateful to Lucy Golden-Mason for doing the phenotypic analysis o f patients 
samples and for providing us with patients blood samples.
I would like to thank Laura Madrigal Estebas and I appreciate her help.
I thank my colleagues in the lab, Tony and Jane. And I thank all the volunteers, who 
provided blood for this study.
This project was supported by the People’s Bureau o f the Great Socialist People’s 
Libyan Arab Jamahiriya. London.
12
This thesis has not been submitted in whole or in part, to this, or any other University 
for any degree, and is, except where stated the original work o f the auther.
Signed:...........
Hameda Asrafel
DECLARATION
13
ABBREVIATIONS
Abbreviation Description
°C Degrees Centigrade
2D Two Domains
3D Three Domains
a-Galcer Alpha-Galactosylceramide
ADCC Antibody Dependent Cellular Cytotoxicity
AO Acridine Orange
APC Antigen Presenting Cells
BCR B Cell Receptor
BSA Bovine Serum Albumin
CD Cluster o f Differentiation
CD Id MHC class I like presenting molecules expressed by APC and other
cells
Cpm Count Per Minute
51Cr 51Chromium
CTL Cytotoxicity T Lymphocyte
DC Dendritic Cells
DMSO Dimethylsulphoxide
DNA Deoxyribonucleic Acid
E/T Effector/ Target
EB Ethidium Bromide
EDTA Ethylenediaminetetra Acetic acid
FACS Fluorescence Activated Cell Sorting
FC Fragment Crystallisable
FCS Foetal Calf Serum
FH Fulminant Hepatitis
FITC Fluorescem Isothiocyanate
FSC Forward Scatter
GPI Glycophosphatidylmositol
HAI Histological Activity Index
HVR1 Hypervariable regionl
HAV Hepatitis A Virus
HBSS Hank’s Balanced Salt Solution
HBV Hepatitis B Virus
HCC HepatoCellular Carcinoma
HCV Hepatitis C virus
HIV Human Immunodeficiency Virus
HLA Human Leukocyte Antigen
HSP Heat Shock Protein
IFN Interferon
Ig Immunoglobulin
IL Interleukin
ILT Immunoglobulin Like Transcrpt
IT AM Immunoreceptor Tyrosine Based Activation Motifs
ITIM Immunoreceptor Tyrosine Based Inhibitory Motifs
IVDA Intra Venous Drug Abuse
KARAP Killer cell Activating Receptor Associated Protein
KIR Killer cell Ig-like Receptors
L Long
L Litre
LAIR Leukocyte Associated Inhibitory Receptor
LAK Lymphokme Activated Killer
LGLs Large Granular Lymphocytes
LIR Leukocyte Inhibitory Receptor
LILR Leukocyte Immunoglobulin Like Receptor
LPS LipoPolySaccharide
LRC Leukocyte Receptors Complex
M Molar
MO Macrophages
MAbs Monoclonal Antibodies
mg/pg milli/ Microgram
MHC Major Histocompatibility Complex
m l milliliter
NCR Natural Cytotoxicity Receptors
NK cells Natural Killer cells
NKRs NK Receptors
NKR+T cells Natural Killer Receptors Positive T cells
NKT cells Natural Killer T cells
PBA PBS/BSA/Azide Buffer
PBMCs Peripheral Blood Mononuclear Cells
PBS Phosphate Buffer Salme
PE Phycoerythrin
16
PerCP Peridin Chlorophyll Protein
RNA Ribonucleic Acid
S Short
SE Standard Error
SEM Standard Error o f the Mean
ssc Side Scatter
TCR T Cell Receptors
TGF Transforming Growth Factor
Th T helper
TLR Toll- Like Receptors
TNF Tumour Necrosis Factor
Tr T regulatory
IChapter 1: Introduction
18
1 .1  Brief introduction to the immune system
There are many different defence mechanisms that protect an individual against 
micro-organisms and potentially harmful material These include physical barriers 
like the skm, phagocytic cells, chemicals and enzymes, which are present prior to 
any exposure to the foreign material. These innate or natural immune mechanisms 
are not enhanced by previous exposure to, nor do they discriminate between, most 
foreign substances. Other defence mechanisms, collectively known as acquired or 
adaptive immunity, have components that are able to recognise structures present 
on foreign material.
The immune system consists o f  a number o f organs and several different cell 
types. The cells o f the immune system, which include tissue cells and white blood 
cells known as leukocytes, develop from pluripotent stem cells The production o f  
leukocytes takes place through two main pathways o f differentiation The 
lymphoid lineage produces T-lymphocytes, B-lymphocytes and natural killer 
(NK) cells while the myeloid pathway gives rise to monocytes and 
polymorphonuclear leukocytes, neutrophils and granulocytes as well as platelets 
(Weir & Stewart 1997)
1.1.1 The innate immune system
The innate immune system, which evolved with the appearance o f multicellular
organisms, can use a variety o f effector mechanisms to recognise the pathogen
and clear an infection These mechamsms rely on cells with killing potential, such
as monocytes, macrophages, neutrophils, dendritic cells (DC) and NK
lymphocytes, and hard-wired detection systems involving cell surface molecules
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that detect common structures found on infections agents or changes in host cells 
that signal danger (Fig.l). Such "pattem-recogmtion receptors" include the Toll­
like receptors that recognise common components o f microorganisms 
(lipopolysaccharides, lipoprotems, glycolipids, flagellin, and bacterial DNA) as 
well as endogenous ligands (heat shock proteins released by damaged or necrotic 
host cells) (Aderem et al. 2000, Akira et al 2001). Engagement o f these 
molecules initiates the activation o f monocytes, macrophages, neutrophils and/or 
DC. The result is the targeted destruction o f the activating organism, infected cell, 
or tumour cell by phagocytosis or the release o f cytotoxic agents. A second type 
o f detection system in the innate immune system is a variety o f activating 
receptors on NK cells that recognise changes to host cells that signify danger such 
as infection or tumour transformation. Ligation o f these natural cytotoxicity 
receptors results in immediate killing o f the infected or tumour cell by the NK cell 
(Moretta et al 2001).
Inflammation is a general term given to the mobilisation and effector activity o f  
the innate immune system in response to signals o f danger. It is initiated by the 
release o f a variety o f polypeptide chemical messengers from activated cells o f  the 
innate immune system and from pathogen-infected and tumour cells These 
chemical messengers include chemokmes and cytokines, which diffuse rapidly 
through the tissues and into the circulation. A key function o f this activity is the 
recruitment o f additional inflammatory cells from other sites o f the body.
Innate immune strategies are activated within seconds o f detection o f danger. It is
likely that such innate defence functions are regular events m the healthy
individual, occurring throughout the body, but perhaps, more frequently at sites o f
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high cell turnover (where there is likely to be a higher incidence o f  mutation) and 
increased exposure to foreign antigens (such as the gastrointestinal tract, liver, 
lungs and uterus) (O'Farrelly and Doherty 2003).
Bacterial lipoproteins 
Bacterial lipoarabinomannans 
LP S (Leptospira, P. gingivalis) 
Peptidoglycan (Gram-positive) 
Zymosan (yeast)
GPI anchor [T. Cruzi)
LPS (Gram-negative) 
Taxol (plant)
Viral proteins 
Hsp60 (host) MICA/
Fibronectin (host) /
Bacterial 
CpG DNABacterial
flagellin
Viral
hemagglutinin MHC class I (host)
Figure 1: Recognition of danger by the innate immune system. Conserved 
pathogen-associated molecules and host cell-surface changes that signify 
danger are recognised by dendritic cells (DC), macrophages (MO) and 
natural killer (NK) cells. Toll-like receptors (TLR) on DC and MO recognise 
viral and bacterial products and stress-inducible molecules released by host 
cells. Natural cytotoxicity receptors on NK cells recognise viral products, 
changes in major histocompatibility complex (MHC) class I expression that 
signify danger, Fc portions of IgG l and IgG3 antibodies, and the stress- 
inducible molecule, MICA. LPS, lipopolysaccharide; GPI, 
glycophosphatidylinositol; KIR, killer immunoglobulin-like receptor; hsp, 
heat shock protein. (Reproduced from O’Farrelly and Doherty 2003).
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1 .1 .2  Adaptive immunity
If a micro-organism or tumour is able to evade the innate defence mechanisms and 
succeeds in expressing a threshold level o f  antigen, inflammation is not resolved 
and the adaptive immune system is initiated. The first and crucial step is the 
activation o f T lymphocytes by antigen presenting cells (APC), which are capable 
o f capturing, processing, and displaying antigen on their cell surface in association 
with MHC molecules. T cells can recognise specific peptide-MHC complexes by 
highly specific clonotypic T cell receptors (TCR) (O’Farrelly and Doherty 2003).
The adaptive immune system uses two different pathways to eliminate 
intracellular and extracellular antigens. Peptides derived from endogenously 
synthesised antigens, such as self-peptides or viral peptides (in infected cells), are 
loaded onto MHC class I molecules in the endoplasmic reticulum and presented 
on the cell surface to CD8+ T cells. CD8+ T cells typically kill the infected or 
tumour cells by either Fas-mediated or perforin/granzyme-mediated induction o f  
apoptosis and release o f interferon-y (IFN-y), which disrupts viral replication. 
Peptides derived from exogenous antigens are processed m the endocytic 
pathway, loaded onto MHC class II molecules and brought to the cell surface for 
presentation to CD4+T cells, which, in turn, activate other cells o f the adaptive 
immune system. MHC class I molecules are expressed on almost all cells o f the 
body and recognition o f antigenic peptides presented by MHC class I renders a 
cell susceptible to lysis by CD8+ T cells. In contrast, MHC class II molecule 
expression is restricted to "professional" APC that can activate CD4+ T cells.
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Three cell types include DC, macrophages and B lymphocytes.
DCs are the most effective o f the APCs for naive T cells. These cells express a 
high level o f  class IIMHC molecules and costimulatory activity. The function o f  
DC is to present antigen to T cells, and the mature DC found in lymphoid tissues 
are by far the most potent stimulators o f naive T cells. DC arise from myeloid 
progenitors within the bone marrow, and emerge from the bone marrow to migrate 
m the blood to peripheral tissues. In these tissues, they have an immature 
phenotype that is associated with low levels o f  MHC proteins and lack o f co­
stimulatory B7 molecules. They are not yet equipped to stimulate naive T cells. 
However, they share with their close relatives the macrophages the ability to 
recognise and ingest pathogens through receptors that recognise features common 
to microbial components (Toll-like receptors), and they are very active in taking 
up antigens by phagocytosis. Upon ingestion o f antigen, DC migrate to the lymph 
nodes, where they acquire mature DC phenotypes. The DC in lymphoid tissue are 
no longer able to engulf antigens by phagocytosis. However, they now express 
very high levels o f long-lived MHC class I and MHC class II molecules; this 
enables them to stably present peptides from proteins acquired from the infecting 
pathogens. They also express very high levels o f  adhesion molecules, including 
DC-SIGN and high levels o f B7 molecules, that make these cells able to potently 
activate naive T cells (Janeway et al 2001).
Macrophages must be activated by antigens before they express class II MHC 
molecules or the co-stimulatory B7 membrane molecule (Goldsby et al. 2000). 
Macrophages that have bound and ingested microorganisms contribute to the 
adaptive immune response by acting as APC.
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Macrophages, like tissue DC, have a variety o f receptors that recognise microbial 
components, including the mannose receptor, the scavenger receptor, complement 
receptors, and several Toll-like receptors. Toll-like receptors bmd conserved 
structures present on pathogens and mediate DC or macrophage activation. This is 
associated with the upregulation o f MHC and costimulatory receptor expression 
and the release o f cytokines such as interleukin-10 (IL-10) and IL-12 that induce 
the activation o f cells o f  the adaptive immune system.
B cells are uniquely adapted to bind specific soluble molecules through their cell- 
surface immunoglobulin. B cells internalise the antigens bound by their surface 
immunoglobulin receptors and then display peptide fragments o f antigen as 
peptide: MHC class II complexes. Because this mechanism o f antigen uptake is 
highly efficient and B cells constitutively express high levels o f  MHC class II 
molecules, high levels o f  specific peptide" self MHC class II complexes are 
generated (Janeway et al 2001). Antibodies are the secreted from o f the B cell 
receptor. The antibody molecule has two separate binding regions. The variable or 
V region recognises and specifically binds to molecules present in the pathogen 
that elicits the immune responses The constant (C) region binds to receptors on 
other cells that can destroy the pathogen. Antibody molecules are Y-shaped 
molecules consisting o f three equal sized portions and form 2 heavy and 2 light 
polypeptide chains. The heavy and light chains contam the antigen binding site, 
and these are termed the Fab fragments, for fragment antigen binding. The Fab 
fragments correspond to the arms o f the antibody molecule, which contain the 
complete light chains paired with the VH and Chi domains o f  the heavy chains.
The other fragment contains no antigen-binding activity but were originally
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observed to crystallise readily, and for this reason was named the Fc fragment (for 
fragment crystallisable). This fragment corresponds to the paired Ch2 and Ch3 
domains and is the part o f the antibody molecule that interacts with effector 
molecules and cells (Janeway et al 2001).
Release o f IL-12 and IL-18 by macrophages and DC promotes the development of
CD8+ cytotoxic T cells (CTL) and CD4+ T helper 1 (Thl) cells. Release o f IL-4 
and IL-6 promotes the development o f CD4+ Th2 cells. Thl cells are generally 
induced by viruses and intracellular bacteria, whereas Th2 cells are induced by 
allergens and helminth pathogens. Thl cells secrete IFN-y and tumour necrosis 
factor-p (TNF-P) and activate macrophages. They also provide helper function for 
B cells production o f complement-fixing and virus-neutralising antibodies o f the 
IgG2a isotype in mice. Th2 cells secrete IL-4, IL-5, IL-6, IL-9, IL-10 and IL-13, 
and are considered to be the true helper cells, activating differentiation and class 
switching o f  B cells to secrete IgE, IgA and IgGl (Abbas et al 1996,0 ’Garra and 
Murphy 1994). A third population o f CD4+ T cells with regulatory function, 
termed Th3 or T regulatory 1 (Trl) cells, produce IL-10 and transforming growth 
factor-p (TGF-P) They suppress Thl responses and have been implicated in the 
maintenance o f immunological tolerance at mucosal surfaces (Maloy and Powrie 
2001).
An important consequence o f the adaptive immune response is protective 
immunity against reinfection and the establishment o f a state o f immunological 
memory. Immunological memory is the ability o f  the immune system to respond 
more rapidly and effectively to pathogens that have been encountered previously,
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and reflects the preexistence o f clonally expanded populations o f antigen specific 
lymphocytes.
1.1.3 Hepatic lymphocyte repertoires
The liver contains a diversity o f  lymphocytes that include conventional a(l T cells, 
B cells, and NK cells that are similar to those found in blood, as well as large 
numbers o f unconventional lymphoid cells that are rarely present in blood. Many 
o f these cells appear to have roles in innate immunity, as evidenced by their 
ability to recognize common, conserved antigenic structures, their ability to 
mediate immediate killing o f target cells, and/or their capacity to release cytokines 
that activate and regulate subsequent adaptive immune responses (Doherty and 
O’Farrelly 2000). These include large numbers ofN K  cells, B -l cells, yô T cells, 
natural killer T (NKT) cells, other T cells that express NK receptors (NKRs), and 
lymphoid DCs (Norris et al 1998, Norris et al 1999, Ishihara et 1999, Hata et 
al 1990, Winnock et al 1991, Ohteki and MacDonald 1994, Tsukahara et al 
1997, Wen et al 1999). Figure 2 shows the relative proportions o f the major 
lymphocyte subsets that are present m the healthy adult human liver compared 
with those found in blood.
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Blood Liver
B cells 
NK cells 5% 
10%
B cells 
6%
NKR+ 
T cells
3%
T cells 
43%
NKR+ T cells 
20%
Fig. 2: Distribution of lymphocyte subpopulations in healthy human blood 
and liver (Reproduced from Doherty and O’Farrelly 2003).
1.2 Natural killer cells
Natural killer (NK) cells comprise approximately 10% o f the mononuclear 
cell fraction in normal peripheral blood (Miller 2001). They contribute to immune 
defence against cancer and viruses. The term “natural killer” cells was originally 
assigned on a functional basis to define lymphoid cells capable o f lysing certain 
tumours in the absence o f  prior stimulation (Moretta et al. 2002). NK cells are 
found in several lymphoid and nonlymphoid compartments, such as the spleen, 
liver, blood and lungs but they are relatively sparsely represented in the lymph 
nodes under normal conditions (Ven den et al. 1991). NK cells are predominantly 
large granular lymphocytes (LGLs) whose proliferation is induced by IL-15 (Fig.
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3). They can mediate cytolysis in the absence o f MHC class I or II antigen 
expression on target cells (Brittenden et al 1996).
In humans, CD56, an isoform o f the human neural cell adhesion molecule serves 
as a tag to distinguish NK cells from other non-T lymphocytes (Rolstad and 
Seaman 1998). Whereas NK cells express CD 16 and CD56, they lack the 
expression o f CD3 and CD4 (Middleton and Curran 2002). Approximately half 
o f human NK cells express CD8 but in contrast to most T cells, which express 
CD8aP hetrodimers, NK cells express CD8aa homodimers (Seaman 2000).
1.2.1 Role of NK cells in immune responses
NK cells lyse target cells that have lost (or express insufficient amounts of) MHC 
class I molecules, as frequently occurs in tumours and in cells infected by certain 
viruses (Moretta et al 2002). NK cells can also directly identify and destroy 
normal MHC-mismatched hematopoietic or lymphoid cells, thus relating to the 
capacity o f  NK cells in vivo to reject transplants o f  bone marrow cells or lymphoid 
cells (Bennett 1987).
NK cells also play an important role in natural surveillance against viral infection 
and neoplasic diseases, and they can play a role in the induction o f specific CTL 
during viral infections (Kos and Engleman 1996, Huang et al 1993). The role o f  
NK cells in early antiviral immune defence mechanisms seems to be crucial. 
Defects in NK cells function can leave the host vulnerable to several viral 
infections and is correlated with a history o f  recurrent infectious diseases 
(Pawelec et al 1998).
NK cells produce higher levels o f  IFN-y in response to IL-12, which is released 
from macrophages and from DC early during viral infections (Orange et al 
1995). IFN-y has antiviral effects both directly and indirectly It disrupts viral 
replication, induces activation o f macrophages, mcreases antigen presentation by 
upregulatmg MHC class I expression in target cells (thus making them more 
susceptible to attack by cytotoxic T cells) and diverts the T-cell response toward a 
Thl response (Rolstad and Seaman 1998)
Although NK cells that can kill sensitive targets can be isolated from uninfected 
individuals, this activity is mcreased by between 20-100 fold whenNK cells are 
exposed to IFN-a and IFN-p, the NK cell-activating factor IL-12 and the T and 
NK cell growth factors IL-2 and IL-15. These cytokines are typically produced in 
virus infections (Fig.3) (Janeway et al 2001). NK cells also exert cell 
cytotoxicity by recognising and inducing lysis o f antibody-coated target cells 
(antibody-dependent cell cytotoxicity) through antibody binding to the receptor 
CD 16 (Fc y receptor III) (Middleton and Curran 2002). NK cell functions are 
regulated by a number o f surface receptors that bind specific ligands expressed by 
target cells (Moretta et al 2001). Binding o f an NK cell to a susceptible target cell 
is followed by an mcrease in phosphoinositide metabolism with a resulting 
increase in cellular calcium concentration, the magnitude o f  which is proportional 
to the sensitivity o f the cell to subsequent lysis (Trincheri 1989).
1.2.2 Mechanisms of NK cytotoxicity
NK cell-mediated cytotoxicity o f target cells takes place by apoptosis induction,
mediated by effectors molecules, which include perforin, granzymes and Fas/Fas
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ligand. NK and lymphokine-activated killer (LAK) cell cytolysis can be 
considered to occur in four stages: 1- target cell binding (adhesion), 2-effector cell 
activation (recognition/signal transduction), 3-delivery o f  the lethal signal to the 
target cell and 4- effector cell detachment and recyclmg (Biron et al 1999, 
Bennett 1987, Graldo and Hiserodt 1989, Orange et al 1995, Young and Cohn
]
1987).
Figure 3: Cytokine-mediated pathways and responses in NK cells. Many viral 
infections induce production of IFN-a/p and these cytokines are good 
inducers of NK cell cytotoxicity. IL-15 induces proliferation of NK cells. IL- 
12 is induced in some, but not all, viral infections and stimulates NK cell IFN- 
Y responses to viruses. Dark solid arrows represent in vivo pathways or 
responses. Broken arrows represent proposed pathways. The X represents 
inhibition (Biron et aL 1999).
1.2.2.1 Perforin/granzyme granules
NK cells eliminate target cells by exocytosis o f  lytic granules, the contents o f  
which kill target cells in a Ca++ -dependent manner. Binding o f NK cell to a 
susceptible target cell infected with intracellular pathogens or to a tumour cell is
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followed by an increase in phosphomositide metabolism, with a resulting increase 
in intracellular calcium. The magnitude o f this increase is proportional to the 
sensitivity o f  the cell to subsequent lysis (Trmcheri 1989). The next stage involves 
polarisation o f preformed lytic granules towards the part o f  the NK cell which is 
m intimate contact with the target cell. The contents o f  the lytic granules, which 
include perforins and granzymes (proteinases and chondroitin sulphate 
proteoglycans) are then released by a process o f exocytosis (Trinchen 1989, 
Robertson and Ritz 1990). Perforins are pore-forming enzymes, which cause the 
appearance o f channels on the target cell membrane and subsequent lysis by the 
release o f soluble factors, mainly cytokines. Granzyme, m contrast, is an effector 
molecule o f activated NK cells. It mainly mediates cell apoptosis.
1.2.2.2 Fas/Fas L
Apoptosis can be induced by the mteraction o f  Fas ligand on NK cells with Fas on 
target cells. Fas ligand is a member o f the TNF family o f membrane-associated 
cytokines, whereas Fas is a member o f the TNF receptor family. Both Fas and its 
ligand are normally mduced during the course o f an adaptive immune response. 
TNF and its receptor TNFR-1 can act m a similar way to Fas ligand and Fas but 
their actions are far less significant.
1.2.3 NK cell receptors
Structurally, there are two families o f  NK cell receptors, the immunoglobulin
superfamily and the C-type lectin receptors. There are numerous members o f the
immunoglobulin superfamily, such as human killer cell Ig-like receptors (KIR),
leucocyte immunoglobulin-like receptor (LILR), leucocyte inhibitory receptor
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(LIR), leucocyte-associated inhibitory receptor (LAIR) and the activating NK 
receptor NKp46 (Fig. 4). The C-type lectin-like receptors, includes NKG2 and 
CD94.
NK cells can be phenotypically defined in humans by their surface expression o f a 
number o f receptors, that are involved in recognition o f target molecules and 
activation/inhibition. These include activating receptors (CD 16, NKG2D, natural 
cytotoxicity receptors (NCRs)), which recognise structures expressed on the target 
cells and transmit intracellular signals that initiate cytotoxicity. They also include 
costimulatory receptors (CD 161) and inhibitory receptors (LIR, LAIR) that, 
likewise, recognise cell-surface structures but generate counter- activating signals 
that block the induction o f cytotoxicity. Finally, NK cells express receptors that 
can be either be activating or inhibitory, such as KIRs and CD94/NKG2 (Fig.4).
In the mouse, the Ly49 family o f  the C-type lectin-like superfamily is expressed 
on NK cells and also on a subset o f  cytotoxic T cells. The repertoire o f Ly49 
expressed by an individual NK cell includes both activating and inhibitory types 
(Natarajan et al 2002). Another group o f molecules in the mouse, the NKR-P1 
family that includes the NK1.1 antigen, has been implicated in activation rather 
than inhibition. Cross-linking o f NK1.1 on NK cells results in cytotoxicity and 
production o f INF-y. However, some o f the NKR-P1 molecules are inhibitory 
(Long 1999).
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Figure 4: NK cells function through a repertoire of activating and inhibitory 
receptors. Activating receptor ligation triggers cytotoxicity while inhibitory 
receptors protect from NK cell-mediated lysis. Multiple receptors are 
involved in the interactions between NK cells and their targets, and 
inhibitory receptor signalling is dominant over stimulating receptor 
signalling. Both classical and nonclassical MHC class I [left side, upper panel] 
and non-MHC ligands [right side, upper panel] are known for many NK cell 
receptors. In contrast to T cells, which require self class I MHC to kill their 
targets, inhibitory KIR can have the opposite effect [lower panel] (Miller 
2001).
1.2.3.1 Human activating receptors
Several membrane receptors have been implicated in NK cell activation, and the 
ligands for some o f these receptors are known as shown in Table 1.
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Table 1: NK cell activating receptors and their ligands
Activating receptors Ligand References
2B4 CD48 Brown et al. 1998
CD16 IgG Perussia et al 1983, 
Lanier et al. 1983
NKG2D Bauer et al. 1999
CD94/NKG2C HLA-E Brand et al 1998
LY6 Karlhofer and yokoyama 
1991
CD44 Galandrini et al 1994, 
Sconcocchoia e ta l  1994.
CD69 Moretta e ta l 1991
NKR-P1 (Rat, mice only) Chambers et al 1989
DNAM-1 Shibuya e ta l  1996
NKP44 Vitale e ta l 1998
NKP46 Sivon e ta l  1997
NKP30 Pend e e ta l  1999
CD2 CD58 Dustin e ta l  1987
The cytoplasmic tail o f  activating receptors contains a charged residue (lysine) 
(Biassoni et al 2000). This residue is involved in the association o f activating 
receptors with signalling molecules containing immunoreceptor tyrosine-based 
activation motifs (ITAM). These signalling molecules include DAP12 (also 
known as killer cell activating receptor-associated protein or KARAP), which is 
mvolved in the transduction o f activating signals (Olcese et al. 1996, Lanier
1998).
CD16 is the human Fc receptor for IgGl and IgG3. It permits NK cells to mediate
antibody-dependent cell mediated cytotoxicity (ADCC) (Timonen et al 1981) by
binding the Fc portions o f these antibodies, while the Fab antigen-binding portions
would be bound to a specific cellular antigen. Thus, the cell is targeted for lysis by
the NK cell. CD 16 is most frequently present on NK cells expressmg low levels o f
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CD56, and this phenotype identifies mature NK cells (Miller 2001). CD 16 is able 
to transduce activating signals through its association with the y subunit o f the 
high affinity IgE receptor (FcsRIy) and the CD3^ subunit (Lanier 1998, OrlofFet 
1990, Wirthmueller et al 1992). The signal transduction pathway occurs via 
activation o f Src-family tyrosine kinases and phosphorylation o f ITAM (Biron
1999)
Recently, three novel immunoglobulin-like type-1 membrane protein NKP46, 
NKP44 and NKP30, whose expression is confined to NK cells have been 
identified, and called natural cytoxicity receptors (NCR) (Vitale et al. 1998, Sivori 
et al 1997, Pende et al 1999). NKP46 and NKP30 are constitutively expressed on 
NK cells, and NKP44 on activated NK cells only (Middleton and Curran 2002). 
The different NCR cooperate in target cell recognition and killing. In most 
instances, blocking o f individual NCR results m partial inhibition o f cytotoxicity 
(Moretta et al. 2001). All three molecules have been implicated m NK cell 
mediated recognition o f  tumour cells because monoclonal antibodies (mAbs) with 
reactivity towards them have the ability to both induce NK cytotoxicity in a 
redirected CTL assay and to mask NK cell killing o f tumour cells (Soloski 2001). 
MAb-mediated cross-linking o f NKP46 results in increases in cytotoxicity, Ca++ 
mobilisation, and cytokine production (Moretta et al 2001).
NKP46 is implicated in the NK mediated lysis o f  human tumours, including lung, 
liver, breast carcinoma, melanoma and EBV-infected cell lines (Biassoni et al
2000). NKP46 is able to recognise viral ligands, such as haemagglutinin o f  
influenza virus or haemagglutinin-neuraminidase o f parainfluenza virus
35
(Mandelboim et al. 2001). The ligands for NKP44 and NKP30 are currently 
unknown.
1.2.3.2 Costimulatory receptors
Human NK activity is also influenced by costimulatory receptors, including 
CD161, CD2, CD1 la/CD18, CD69 and CD49d/CD29. CD161 is involved m 
triggering cytotoxicity. IL-2 and IL-12 differentially modulate CD161 expression, 
suggesting a mechanism whereby these cytokines modulate NK cell activity 
(Azzoni et al. 1998)
1.2.3.3 Inhibitory receptors
The LIR/ Immunoglobulin like transcrpt (ILT) family was discovered by 
identifying receptors that bind the class I homologous cytomegalovirus UL18 
protein (Cosman et al 1997). At least eight LIR genes have been identified 
(Colonna et al 1997). LIRs are encoded in a gene complex centromeric to the 
KIR complex (Wagtmann et al 1997), and LIR protems contain various numbers 
o f extracellular Ig-like domains. LIR-1 (ILT-2), a member with 4 Ig-like domains, 
is found on NK cells, monocytes, DC, and B cells (Miller 2001). It binds several 
different human leukocyte antigen (HLA) class I molecules, including HLA-G. It 
inhibits CD16-mediated NK cells activation. LIR-1 also inhibits T cell 
cytotoxicity induced by the TCR, and intracellular Ca^ mobilisation in B cells 
triggered by the B cell antigen receptor (BCR) (Colonna et al 1997) ILT3 has 
two Ig domains and is expressed in monocytes and DC (Celia et al 1997). ILT4 is 
less widely expressed than ILT2 and binds HLA-A and HLA-B allotypes 
(Colonna et al. 1998).
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Leukocyte associated immunoglobulin-like receptor -1 (LAIR-1) has a similar cell 
distribution to LIR-1 and contains immune receptor tyrosme-based inhibitory 
motifs (ITIMs), but LAIR-1 does not appear to bind class I molecules 
(Meyaard et al. 1997). LAIR -1 shares its size (40KDa) and other properties with 
an inhibitory receptor called p40 that is expressed on hematopoietic cells and 
inhibits NK and T cell responses (Poggi et al. 1995, 1997).
1.2.3.4 Stimulatory/inhibitory receptors
The stimulatory/inhibitory receptors specific for HLA class I consist o f two 
structurally distinct families o f  molecules, the killer cell Ig-like receptors (KIR) 
and the killer cell lectin like receptors (CD94/NKG2) The main function o f HLA 
class I specific inhibitory receptors is to avoid damage to normal tissue. The lack 
o f expression, or simply the expression o f inadequate amounts, o f  MHC class I 
molecules can make cells susceptible to NK mediated killing (Moretta et al
2001).
KIR specifically recognise different groups o f HLA class alleles (Colonna and 
Samaridis 1995, Dohnng et al 1996, Wagtmann 1995). All mature human NK 
cells express at least one inhibitory receptor specific for self HLA class I (Moretta 
et al 2002). This allows the whole NK cell pool o f  a given individual to sense the 
loss o f  even single class I alleles on self cells (Moretta et al 1996). The HLA 
class I specific inhibitory receptors block NK mediated cytotoxicity and cytokine 
secretion (Biassoni et al. 2000).
The genes coding for KIRs have been mapped to chromosome 19q l3 ,42 in a
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region called leukocyte receptors complex (LRC) (Barten e ta l  2001, Wende et 
a l  1998).
KIRs can signal either inhibition or activation o f the NK cell when class IMHC is 
recognised (Fig.5). Inhibitory KIR isoforms have long cytoplasmic tails that 
contain ITIMs that recruit cytoplasmic tyrosine phosphatases which signal 
inactivation o f NK cell function. In contrast, stimulatory KIRs have short, 
truncated cytoplasmic tails lacking such inhibitory motifs, and these molecules 
associate with DAP 12, a protein with an ITAM that enhances cell activation. At 
least 14 KIR family members have been identified and these include 8 inhibitory 
and 6 noninhibitory receptors (Valiante et al 1997).
Figure 5: NK cell stimulatory and inhibitory receptors. The stimulatory 
receptor A with immune receptor tyrosine-based activation motif (ITAM) is 
inhibited by inhibitory receptor B with immune receptor tyrosine-based 
inhibitory motif (ITIM) (Long 1999).
activation Inhibition
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KIRs are named according to whether they have two domains (2D) or three 
domains (3D) in their extracellular portion and to whether they possess a short (S) 
or long (L) cytoplasmic tail (Fig 6) (Middleton and Curran 2002). They have also 
been named according to the CD nomenclature system as CD158a, CD 158b, etc., 
based on an approximate centromeric-telomeric order o f the genes on 
chromosome 19.
Unfortunately, the CD nomenclature does not reflect structure, function, 
expression or locahsation. This system also presents the possibility o f  confusion 
when mAbs against the CD158a and CD158b are used, since each binds to the 
extracellular domins o f  several different KIR molecules (Carrington and Norman 
2003).
2DL 2DS 2DL4 3DL 3 PS
Figure 6: KIR receptors and their domains (Middleton and Curran 2002).
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The shared structure and sequence similarity indicates that KIRs evolved from a 
common ancestor (Middleton and Curran 2002). The topology o f the domains and 
their relative orientation resemble those found m haematopoietic receptors such as 
human growth hormone receptor (De Vos et al. 1992), erythropoietin receptor 
(Livnah et al 1999) and prolactin receptor (Somers e ta l  1994)
KIR2DL1 and KIR2DL2 bind different HLA-C allotypes, and this discrimination 
o f  binding resides in the first Ig domain o f  these KIR molecules (Winter et al 
1998, Biassom et al. 1997, Boyington et al 2000, Miller 2001). The KIR with 
three Ig domains (KIR3DL1) recognizes HLA-B allotypes that belong to the Bw4 
serologic specificity (Long 1999). The ligand for KIR2DL4 is thought to be HLA- 
G, and that for KIR3DL2 is HLA-A3 (Selvakumar et al 1996, Litwm et al 
1994). Ligands for the other receptors, including the recently found KIR2DL5, are 
unknown(Vilches e ta l  2000).
CD94 and NKG2 are lectin-like, disulfide-linked heterodimers expressed on 
human and rodent NK cells and a subpopulation o f T cells (Natarajan et al 2002) 
CD94/NKG2 heterodimers recognise non-classical class I HLA-E molecules 
bound with peptide leader sequences from HLA -A, B, C and G (Leibson 1998, 
Brand et al 1998, Borrego et al 1998). The CD94/NKG2 receptor is designed to 
gauge the overall level o f  HLA class I synthesis in cells (Long 1999). CD94 
essentially lacks a cytoplasmic domain, thus lacking signal transduction capacity. 
It dimerises with NKG2A (containing ITIM) or with NKG2C/DAP12 (containing 
ITAM), and can these function as an inhibitory or stimulatory receptors.
NKG2D is a member o f the C-type lectin- like family o f  NK receptors. It is also
s
expressed by y8 T cells, some CD8+T cells, and NKT cells. NK cell triggering via 
NKG2D has been shown to over ride the negative signalling generated by the 
engagement o f HLA class-I-specific inhibitory receptors (Bauer et al. 1999). The 
NKG2D gene is located adjacent to NKG2A, B and C within the NK complex. Its 
encoded protein shows little homology to other NKG2s and does not pair with 
CD94. (Natarajan et al 2002). Various families o f cell surface ligands have been 
identified, including the MICA/B and ULBP proteins expressed predominantly 
(but not exclusively) by cells o f  epithelial origin (Bauer et al 1999). Some o f  
these ligands are upregulated on transformed, infected or distressed cells, and 
ligand expression by a tumour cell leads to activation o f NK cells and CD8+ T 
cells and induction o f tumour immunity (Diefenbach et al. 2002). A key issue 
with respect to NKG2D function is whether it provides a stimulatory or 
costimulatory signal to responding cells. Its engagement in NK cells and 
macrophages results in direct cellular activation; in contrast, engagement o f  
NKG2D on T cells costimulates effector T cell function (Jamieson 2002). This 
versatility is achieved by the selective expression o f DAP 10 and DAP 12 by T 
cells and NK cells on different cells and by their distinct association with 
alternative isoforms o f NKG2D (Diefenbach et al. 2002).
1.3 Natural killer receptor positive T cells (NKR+T cells)
A proportion o f  T cells can express NK cell stimulatory, costimulatory and 
inhibitory receptors (NKRs). Human NKR+T cells can be CD8+, CD4+ or CD4‘ 
CD8', they express ap or y5 TCRs and most express activated/memory T cell
41
phenotypes They possess a variety o f NKRs, including CD 16, CD56, CD161, 
NKG2D/CD94, and KIR receptors for MHC class I molecules, such as KIR2DL1, 
KIR2DL2, KIR2DL3 and KIR3DL1 (Mingari et al 1995, Doherty and O’Farrelly 
2000, Lanier et al. 1986, Lanier et al. 1987, Ortaldo et al. 1991, Mingari et al 
1996, Norris e ta l  1999)
NKR+ T cells have multiple effector activities. They can be rapidly activated 
without the need for prior antigen priming. They are capable o f  MHC-unrestricted 
cytotoxicity and the release o f multiple cytokines (Ishihara et al 1999, Dunne et 
al 2001, Doherty et al. 1999). CD56+ T cells and CD161+ T cells can be induced 
by IL-2, IL-12, or IL-15 to directly kill a variety o f tumour cell types and thus 
they display properties o f  LAK cells (Doherty et al 1999, Satoh et al 1996, 
Dunne et al 2001). They are also capable o f  TCR-mediated cytotoxicity.
Their potent cytotoxic activities appears to be kept under regulatory control via 
inhibitory signals through KIRs and CD94. The majority o f  CD56+ and CD161+T 
cells produce IFN-y, TNF-a, and IL-2 within hours o f activation, indicating that 
they can function in inflammatory or Thl immune responses (Doherty et al. 1999, 
Nuti et al 1998). A significant proportion (-15 %) o f NKR+ T cells produce the 
Th2 cytokine IL-4. Since NKR+ T cells can be rapidly activated without the need 
for prior antigen priming to produce large amount o f Thl or Th2 cytokines, it is 
thought that they represent a bridge between the innate and adaptive immune 
systems by influencing Thl/Th2 cell differentation (Fig.7) (Doherty and 
O’Farrelly 2003).
Although NKR+ T cells display properties o f  cells o f  the innate immune system, 
they express memory T cell phenotypes (Norris et al. 1999) and homing
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chemokine receptors (Campbell et al. 2001), suggesting that they may be antigen- 
specific memory T cells. NKR expression may therefore identity a subset o f 
memory T cells that have acquired the less specific and more rapid and potent 
effector functions characteristic o f NKR+ T cells (Doherty and O’Farrelly 2003).
IL-2
IL-12
IL-15
Figure 7: Natural killer receptor-positive (NKR+) T cells can initiate and 
regulate innate and adaptive immune responses in humans (Doherty and 
O ’Farrelly 2003).
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NKT cells are a population o f T cells that share some characteristics o f NK cells 
and have immunoregulatory functions (Bendelac 1995, Bendelac et al 1997, 
MacDonald 1995). These cells are thought to be antitumour effectors (Bendelac 
et al 1997). The TCRs o f  NKT cells are specific for glycolipid antigens bound by 
the MHC class I-like protein CDld (Wilson et al 2002). CDld molecules are 
encoded outside o f the MHC gene locus, and their expression is largely restricted 
to thymocytes, B cells, macrophages, DC and hepatocytes. The physiological 
ligands that are recognised by NKT cells in the context o f  CDld remain unknown 
(Wilson et al. 2002). Most NKT cells recognise CDld in conjunction with 
hydrophobic ligands (glycolipids) (Benlagha et al 2000, Burdin and Kronenberg
1999). One population o f NKT cells expresses rearranged TCRs that are limited in 
heterogeneity using an invariant TCR a-chain (V a24Jal8 in human, V a l4Ja l8  
in mouse) paired with one o f a limited number o f P-chains (Vpl 1 in humans, Vp8 
in mouse) (Soloski 2001). These invariant TCR-expressing NKT cells account for 
about 5% o f peripheral blood T cells in mice but <0.1 in human (Kenna et al 
2003). NKT cells are more abundant in the thymus, hver, and bone marrow but 
not in lymph nodes (Fig. 8) (Wilson et al 2002).
A glycolipid extracted from sponges, alpha- galactosylceramide (a-GalCer), and
its synthetic equivalent KRN7000, bind CDld molecules and stimulate NKT cells
(Brossay et al 1998, Spada et al 1998).Studies on the interaction o f the NKT TCR
and CDld with a-GalCer have demonstrated that the acylchain o f a-GalCer
interacts with CDld and that its carbohydrate portion is recognized by the
invariant TCR (Joyce 2001). a-GalCer stimulates antitumour responses in mice by
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1.4 Natural killer T  cells (N K T  cells)
Figure 8: CDId molecules present lipid antigens to natural killer T (NKT) 
cells. NKT cells recognise CDId using invariant V a l4 /V p 8  T cell receptors in 
mouse and V a 2 4 /V p il in humans (Wilson et al. 2002).
activating NKT cells (Soloski 2001). Murine models, NKT cells mediate
cytotoxicity against tumour cell lines in vitro (Bendelac et al. 1997, Smyth et al.
2000), suggesting an important role for these cells in tumour rejection (Godfrey et
al. 2000). They constitutively express Fas-L and can kill Fas-expressing target
cells, and they can also kill tumour target in a perforin dependent manner (Smyth
et al. 2000). Recent preclinical studies in mice have revealed significant efficacy
o f a-GalCer for treatment o f metastatic cancers and infections, and for prevention
of autoimmune diseases. These findings suggest that appropriate stimulation o f
NKT cells could be exploited for prevention or treatment o f human diseases
(Wilson et al. 2002). The potential usefulness o f a-GalCer in immunotherapy
resides on its ability to activate NKT cells, which secrete IFN-y which in turn
activate cytotoxic NK cells. a-GalCer is not a physiological ligand o f NKT cells
because mammals are unable to synthesize such a-anomeric glycosphingolipids
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(Wilson et al 2002). NKT cells appear to participate in immune responses to a 
range o f different mfectious agents, including mycobacteria, the protozoan 
parasites Leishmama (Ishikawa et al 2000), and Tyrpanosoma cruzn (Duthrne et 
al 2002), the spirochete Birelia burgdorferi (Kumar et al. 2000), the fungal 
pathogen Cryptococcus neoformans (Kawakami et al 2001), diabetogenic 
encephalomyocarditis virus (Exley et al 2001), and respiratory syncytial virus 
(Johnson et al 2002).
One striking property o f  NKT cells is their capacity to rapidly produce a spectrum 
o f cytokines, including IL-4, IL-10, IL-13, INF-y and TNF-a, upon TCR 
engagement (Godfrey et al 2000, Joyce 2001, Bendelac et al 1997). This makes 
NKT cells important potential regulatory cells o f the adaptive immune system. As 
explained above, na'ive CD4+ T cells that are activated in the presence o f  IL-12 
(from APC) or IFN-y become committed to differentiate into Thl cells, whereas 
CD4+ T cells activated m the presence o f IL-4 become committed to differentiate 
into Th2 cells. Because NKT cells can secrete both IFN-y and IL-4, these cells can 
promote Thl responses under certain conditions and Th2 responses in others 
(MacDonald 1995). A significant amount o f evidence indicates that NKT cells 
play a critical role in the regulation o f autoimmmune responses (Godfrey et al 
2000, Joyce 2001, Bendelac et al 1997). Although the precise mechanism by 
which NKT cells regulate autoimmumty remains to be established, most studies 
have provided evidence for a crucial role o f the cytokines IL-4, IL-10 and IL-13. 
Defects in NKT cell numbers and function have been observed in patients with 
systemic sclerosis, type 1 diabetes, rheumatoid arthritis and lupus (Wilson et al
1.5  Hepatitis C
The hepatitis C virus (HCV) is a positive stranded RNA virus with a genetic 
structure similar to that o f  flaviviruses. The single stranded RNA genome o f HCV 
is approximately 10000 nucleotides in length. The virus is highly variable with 
nucleotide sequence varying considerably from one isolate to another, forming the 
basis for at least six known genotypes and these genotypes may also be 
subdivided into subtypes. In addition, nucleotide variability may be present in 
viruses circulating within an individual. These are referred to as quasispecies and 
may reflect the consequences o f ongoing immune surveillance and viral mutation. 
Some genotypes such as la, lb and 4 seem to be less responsive to interferon 
therapy and infection with genotype lb is more likely to lead to cirrhosis or 
hepatocellular carcinoma (HCC) (Bisceglie 1998)
HCV protein is translated as one large polyprotein composed o f 3010 amino acids. 
Viral protein translation is initiated by the ribosome binding to the internal 
ribosomal entry site in the 5' non-translated region (Fig. 9). The viral polyprotein 
is subject to processing to make up ten polypeptides. The virus structural proteins 
can be cleaved by the host signal peptidase and it includes a nucleocapsid core 
protein and two envelope proteins, designated El and E2, which coat the virus 
Extensive variation is present in the envelope glycoproteins o f  HCV, particularly 
within the amino-terminal region o f E2 known as hypervariable region 1 (HVR1) 
(Foms et al 1999). HVR1 is composed o f about 30 amino acids located at the N- 
terminus o f  E2. This region appears to operate as an antibody epitope (Kohara
1 .5 .1  Hepatitis C  virus
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2000). The non-structural proteins seem to be critical for viral replication and
I
include a viral protease (Fig. 9) (Bisceglie 1998).
HCV infection may occur through binding o f the envelope protein E2 to the 
cellular receptor CD81 (Kohara 2000). CD81 is a widely expressed cell surface 
protein, a tetraspanin which is conserved among different mammalian species 
(Meola et al 2000). Like all tetraspanins, CD81 is organised in four highly 
hydrophobic transmembrane domains, which force the protein to traverse the 
membrane four times (Petracca et al 2000) and forms a small extracellular loop 
and a large extracellular loop on the cell surface (Masciopinto et al. 2001). The 
large extracellular loop o f CD81 is sufficient to bmd HCV via interaction with the 
major virus envelope protein E2 (Pileri et al. 1998).
1 192 384 7 4 7 ^ ^ 8 1 0  y __ .1027_________ 1658 ^ S 4 ^ / 21973 2420 3010
[core I E l I E2 I IN S2 I N S3 f |nS4B IN SSA I N S 5 B  1
♦ ♦ 44 T _  RNA helicase ' n  4 f  RNA polymerase
signal peptidase serine protease
structural protein non-structural protein
Figure 9: Organisation of the HCV genome. The 9600 nucleotide genome is 
translated as a single polyprotein composed of 3010 amino acids. The viral 
polyprotein is processed to make 10 proteins, which include a nucleocapsid 
core protein, two envelope peptides and non-structural peptides. 1RES, 
internal ribosomal entry site.
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1.5.2 HCV disease
HCV infection is endemic in most parts o f the world, with an estimated overall 
prevalence o f 3% (Wasley and Alter 2000). It is estimated that over 170 million
s
people are infected (Klenerman et al 2002). Significantly higher rates o f infection 
have been found in parts o f  Eastern Europe and Africa (Alter 1995) while Egypt 
seems to have one o f the highest prevalence rates o f all, approaching 15% o f the 
general population. Nearly 4 million people are infected with HCV in the USA  
(Bisceglie 1998). Most infections are found among persons 30-44 years old, 
indicating that the risk for HCV infection was greatest in the relatively recent past 
(10-30 years ago) and primarily affected young adults (Wasley and Alter 2000).
HCV is most frequently transmitted by contact with contaminated blood among 
populations o f  intravenous drug users, and it is acquired rapidly so that within 6 to 
12 months up to 80% o f users are infected (Klenerman et al 2002). Invasive 
medical procedures, particularly those performed in non-medical settings or 
involving blood transfusion, may also transmit the hepatitis C virus (Gabriel et al
1996). Health care workers are at slightly increased risk o f  HCV infection 
compared with the general population, and the rate o f  infection following needle 
stick injury is 5 to 10%. HCV may also be transmitted from mother to infant 
(Bisceglie 1998). While it has been difficult to demonstrate that HCV is a sexually 
transmitted disease, individuals with multiple sexual partners are clearly at greater 
risk o f having HCV (Alter et al 1990).
Although HCV infection is very common, it rarely presents acutely, as the disease 
is usually not accompanied by overt jaundice and patients rarely seek medical
attention at early stages o f the disease (Lechner et al 2000)
HCV is able to set up chronic infection in about 80% o f those infected (Gruener 
et al 2001), the remaining 20% appear to be able to clear the viruses and recover. 
The clinical course o f chrome hepatitis C is highly variable. In about 70% of  
patients with chronic HCV infection the disease is mild and stable over several 
decades, whereas in the remaining 30% it is more rapidly progressive (Farci et al
2000). Very rarely HCV causes fulminant hepatitis (FH), the most severe form o f  
hepatitis. In an estimated 15% to 20% o f persons infected with HCV, the infection 
progresses to cirrhosis. Alcohol intake is an important factor in this progression 
(Herrine 2002). The initial appearance o f hepatic fibrosis seems to be an 
important predictor o f the development o f cirrhosis (Yano et al 1996). HCC may 
develop in 1.2 to 4% o f patients infected with HCV (Bisceglie 1997). Liver failure 
and HCC appear mainly in individuals with cirrhosis, and because cirrhosis may 
take many years to develop, HCV infection may be silent for decades (Seeff et al 
1992). In addition to causing liver disease, HCV infection is frequently associated 
with the development o f autoimmune diseases such as sjogren syndrome and 
systemic lupus erythematosus (Trejo et al. 2003).
In 1977, a cohort o f Irish women was infected with HCV genotype lb via
contaminated anti-D immunoglobulin. (Barrett et al. 2001). The source o f the
infection was identified as an acutely infected female. As part o f a voluntary
serological screening programme, 704 individuals were identified as seropositive
for exposure to the HCV. Of these, 55 4% were found to be positive for the viral
genome 17 years after exposure. Of these women, 98% had evidence o f
inflammation, but surprisingly, 49% showed no evidence o f  fibrosis (Fanning
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1.5.3 Diagnosis o f hepatitis C
Two types o f tests are available for the laboratory diagnosis o f HCV infection: the 
detection o f antibody to various HCV antigens, and molecular methods to detect 
and quantitate the nucleic acid o f the virus (American Academy o f Pediatrics
1998). There are several sensitive enzyme-linked immunoassays available for the 
detection o f anti-HCV antibodies based on the use o f recombinant viral proteins in 
a microtitre plate or bead format (Silva et al. 1994). Molecular testing for HCV is 
used to confirm a positive result on antibody testing and to provide prognostic 
information for treatment (Herrine 2002).
Liver biopsy is a very important tool in the assessment o f patients with chronic 
HCV because it permits determination o f the degree o f inflammation (grade o f  
hepatitis) and the amount o f fibrosis present (stage o f hepatitis) (Bisceglie 1998). 
Most specialists prefer to include an examination o f liver histology in the 
management o f patients with chronic HCV infection to aid prognostic and 
treatment decisions (Herrine 2002).
1.5.4 Treatment o f  hepatitis C
Interferon alpha (IFN-a) with ribavirin are the only products licensed for the
treatment o f  chronic HCV infection in adults, and up to 66% o f patients treated
have a sustained response (Balistreri 1994, Poynard 1998, McHutchison 1998).
IFN-a appears to augment host immune responses enabling the elimination o f
HCV. The use o f IFN-a is associated with a decrease in serum aminotransferase
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2002).
activity and a decline m HCV RNA to undetectable levels in some but not all 
individuals (Hoofiiagle et al 1986). No controlled trials o f IFN-a therapy in 
children with chronic hepatitis C have been conducted, and IFN-a is not approved 
by the food and drug administration o f the USA for use in individuals aged less 
than 18 years (American Academy o f  Pediatrics 1998). The optimal response is 
defined by persistently normal serum amino transferase concentrations and 
absence o f HCV RNA from serum at the end o f therapy and for at least 6 months 
thereafter (Bisceglie 1998). Factors associated with a good chance o f responding 
to interferon include the absence o f  cirrhosis, lower pretreatment serum HCV 
RNA levels, and infection with HCV genotypes other than type 1 (Bennett et al
1997). Several forms o f interferon are available, but most seem to have similar 
effects with only small differences in response rates.
Other adjuncts to IFN-a have also been tested and these mclude non-steroidal 
anti-inflammatory agents, nacetyl cysteine, ursodeoxycholic acid, and iron 
reduction therapy. Side effects o f IFN-a therapy mclude myalgias, fever, 
nausea, irritability and depression (Herrine 2002).
The current standard o f pharmacologic treatment o f chronic HCV is weekly 
subcutaneous IFN-a in combination with daily oral ribavirin. Ribavirin is a 
guanosine analogue, and is active against various RNA and DNA viruses (Herrine 
2002, Manns etal 2001, Fried et al 2002). When ribavirin is used together with 
IFN-a, there is a significantly higher rate o f sustained response than with 
IFN-a alone (Brillanti et al 1994, Reichard e ta l  1988).
For patients with advanced liver disease, liver transplantation is sometimes the
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only therapeutic option. Hepatitis C is now the most frequent indication for liver 
transplantation among adults in many western countries (Bisceglie 1998).
No vaccine exists for the prevention o f HCV infection.
1.5.5 Host immune response to HCV
Antiviral immune responses comprise a large array o f cell types, effector 
functions, and signalling molecules as summarised in Fig. 10 (Klenerman et al.
2002).
Figure 10: Players in the immune response against HCV and their roles 
(Klenerman et al. 2002).
The innate and adaptive immune responses are believed to play a crucial role in 
the host response to viruses and other pathogens. Although HCV infection induces
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strong cellular and humoral immune responses (Alter 1995, Ferrari et al 1994), 
they are generally insufficient to eradicate the virus or to prevent reinfection 
(Farci et al. 1992, Prince et al 1992). The mechanisms responsible for the high 
rate o f  viral persistence and for the variable clinical course o f hepatitis C are 
unknown, but are thought to represent a complex interplay between viral diversity 
and host immunity.
Multiple potential mechanisms have been postulated to explain why people 
infected with HCV fail to resolve this virus, despite generating both cellular and 
humoral immune responses. One possibility is the mutability o f  the RNA o f this 
virus that leads to quasispecies that evade immune recognition (Weiner et al.
1991, Kumar et al 1994). Another possibility is that HCV inhibits crucial immune 
functions. HCV-encoded proteins such as envelope protein E2, the nonstructural 
protein and core protein have been repoted to have immunosuppressive potentials 
(Gale et al 1997, Taylor et al 1999, Large et al 1999). HCV is able to replicate 
in immune cells, such as mononuclear cells and B cells (Sung et al 2003, Hamaia 
etal. 2001).
Replication o f  HCV in immune cells may serve to transport HCV to lymphoid 
tissue where it can inhibit immune responses or to sequester virions from such 
recognition (Fig. 11) (Hahn 2003).
1.5.6 Quasispecies
A feature o f hepatitis C is the simultaneous presence o f different but closely
related viral variants, commonly defined as quasispecies. This genetic
heterogeneity is a result o f  the accumulation o f mutations during viral replication.
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This high mutation rate, which is characteristic o f RNA viruses, can be attributed 
to an error-prone RNA-dependent RNA polymerase that lacks proofreading 
activity (Rice 1996). The existence o f  extensive HCV quasispecies has been 
suggested as a potential mechanism for viral persistence, mainly by allowing the 
virus to escape the host immune response (Manzin et al. 1998, Ray et al. 1999).
B* and T*ceH recognition Immunomodulatory strategies
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Fig. 11: HCV evolves strategies to evade and modulate immune responses. 
Multiple potential mechanisms have been postulated to account for the high 
rate of persistent HCV infection. For example, mutations in E2 HVR1 are 
associated with viral escape from neutralising anti-E2 antibody. Another 
strategy is the modulation of immune cell (e.g. T cell and NK cell) function by 
HCV gene products; the binding of HCV core protein (C) to the complement 
receptor gClqR inhibits T cell function, whereas insufficient cytokine 
production by DCs or M<t>s may be also involved in T cell dysfunction. In 
addition, the E2-CD81 intraction is capable of impairing NK cell activation 
(Hahn 2003).
Extensive variation in the envelope glycoproteins o f HCV has been demonstrated 
(Hijikata et al. 1991, Weiner et al. 1991), particularly within HVR1. Indeed,
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sequence analysis o f  HVR1 has been used extensively to characterise the 
quasispecies distribution o f HCV in infected patients (Foms et al 1999). Such 
hypervariability within the E2 protein may be under selective pressure from 
protective B cell or T cell responses and be able to escape immune recognition by 
rapid mutation at this antigenic site. Diversity o f  viral HVR1 quasispecies is 
increased in the acute phase o f HCV infection in patients who develop chronic 
hepatitis, compared with acute resolving cases, suggesting that, in patients who 
develop a chronic HCV infection, the immune system is not capable o f  controlling 
the infection because o f the emergence o f multiple escape mutants (Foms et al
1999). Antibodies against the E2 protein o f HCV can be detected in infected 
individuals. In a study o f the acute phase o f HCV infection, CTL activity agamst a 
particular epitope within HVR1 was significantly stronger in patients who cleared 
HCV infection than in those who developed a chrome infection (Tsai et al. 1998), 
suggesting that T cell responses against HVR1 o f the E2 protein are critical in 
determining the outcome o f HCV infection.
1.5.7 Role o f antibodies in immunity against HCV
Antibodies have a role in the containment o f HCV infection (Hadlock et al 2000). 
While antibodies are produced in HCV infection, and probably mediate selective 
pressure on viral sequences (Farci et al 2000), few studies have demonstrated an 
important role for the humoral immune response in the control or clearance o f  
infection. HCV persistence and hepatitis progression are observed even when 
circulating antibodies to HCV are present (Hahn 2003). Moreover, at least 70% o f  
HCV infected individuals have circulating autoreactive antibodies (Cacoub et al
2000). This may be due to an effect o f HCV infection directly on autoreactive B
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HCV infection is associated with disturbances o f B lymphocyte activation and 
function. It has been proposed that these abnormalities reflect either chronic 
antigenic stimulation or aberrant signalling through the B cell coreceptor; the 
latter which may be mediated by binding o f the HCV E2 glycoprotein to CD81 
(Ni et al 2003). On B cells, CD81 associates with CD 19 and CD21, forming a 
complex which is known to lower the threshold o f  activation by B cell receptor- 
mediated stimuli (Fearon and Carter 1995).
1.5.8 Role o f T cells in immunity against HCV
T cells are thought to be the main players m antiviral defence. Studies o f patients 
and chimpanzees (the only animal model o f  HCV infection) who spontaneously 
cleared acute HCV infection mdicate that successful control o f  the infection 
requires a broad response o f helper and cytolytic T cells (Lechner et al 2000, 
Cooper et al 1999, Takaki et al 2000). Recent studies have provided compelling 
evidence that resolution or persistence o f HCV infection depends on the strengths 
o f inflammatory T cell (Thl) and CTL responses that are generated in the liver 
soon after infection. Patients who clear the virus exhibit vigorous CD4+ Thl cell 
and CD8+ CTL responses against multiple regions o f  the HCV polyprotein within 
weeks o f infection. In contrast, a lack o f an optimal T cell response to HCV is 
associated with the development o f cirrhosis during chronic HCV infection 
(Sreenarasimhaiah et al 2003, Cooper et al 1999, Cemy and Chisari 1994).
The CD8+ CTL immune response is an important mechanism for clearance o f
cells (Wack et al 2001)
most viruses. However, in the case o f  chronic HCV infection, the virus persists 
despite the presence of a detectable CD8+ CTL response (Chang et al. 2001) 
Cooper et al (1999) showed that CTL responses in chimpanzees are essential for 
clearance o f HCV They monitored antibody and intrahepatic CTL responses 
during acute infection in chimpanzees Two animals who terminated infection 
made strong CTL but poor antibody responses. In both resolvers, CTL targeted at 
least six viral regions. In contrast, animals developing chronic HCV generated 
weaker acute CTL responses agamst fewer viral epitopes. Extensive analysis o f  
the fine specificity o f the CTLs in one resolver revealed nine peptide epitopes and 
restriction by all six MHC class I allotypes o f  the chimpanzee. Every CTL 
specificity seen during acute HCV persisted in normal liver tissue more than 1 yr 
after resolution. These results suggest that CD8+ CTL are better correlated with 
protection against HCV infection than antibodies.
The role o f CTLs for controlling early HCV infection has been established for a 
small number o f patients (Thimme et al 2001). However, several studies revealed 
that the effector function o f HCV-specific CD8+ T cells is significantly impaired 
during HCV infection (Wedemeyer et al. 2002, Urbani et al 2002, Gruener et al.
2001). The numbers o f intrahepatic CD8+ T cells are lower in patients with 
chronic HCV disease compared with healthy livers (Deignan et al 2002)
When compared to the hepatitis B virus (HBV)-specific CD8+ T cells, HCV- 
specific CD8+ T cells express significantly less perforin and show evidence of  
diminished effector function (Hahn 2003) In some situations, CD8+T cells 
responses show a reduced capacity to secrete antiviral cytokines early in the 
infection (Klenerman et al. 2002). One study demonstrated that individuals with a
histology o f fibrosis/cirrhosis showed a significantly lower CD8+ CTL responses 
to five epitopes derived from the core, NS3, NS4 and NS5 proteins as compared 
with patients with histology o f mild inflammation (Sreenarasimhaiah et a l  2003).
Several studies have shown that CD4+ T cells also play an important role in the 
immune response against HCV infection (Eckels et al 2000). A CD4+ T 
lymphocyte response directed against all o f  the putative HCV proteins occurs in 
chronically infected patients despite their failure to clear the virus (Cemy and 
Chisari 1994). The HCV-specific CD4+ T cell response in infections with 
subsequent viral clearance has been shown to be more vigorous than in chronic 
HCV infections (Nakamura and Imawari 2000) CD4+T cell responses o f Thl- 
type are important determinants o f HCV resolution, since Thl cells produce IFN-y 
and IL-2 and promote CTL activity (Diepolder et al. 1995, Missale et al 1996). It 
has been shown that chronic HCV infection may be associated with a predominant 
CD4+ Th2 response, that induces production o f IL-4, IL-5 and IL-10 and 
promotion o f antibody responses (Tsai et al 1997). The HCV core and NS4 
proteins appear to be most immunogenic for peripheral blood lymphocytes, and 
NS4-specific CD4+ T lymphocytes are preferentially compartmentalised to the 
liver (Spengler et al 1996). MacDonald et al (2002) examined the CD4+ T cell 
responses to the HCV core protein in a cohort o f women infected with a single 
genotype o f  HCV. CD4+ T cells from HCV infected patients secreted IFN-y in 
response to peptides from 4 immunodominant regions o f the core protein, and 
these responses were stronger in persistently infected women. IL-10 was also 
produced by CD4+ T cells from HCV infected subjects in response to the same 
core peptides. Furthermore, HCV core-specific CD4+ T cell clones secreted either
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IFN-y or IL-10 but not IL-4. These findings demonstrate that T helper type 1 and 
regulatory T cells are induced against the same epitopes on the core protein during 
HCV infection
Other T cells population that reside in the liver are likely to play a key role in 
determining whether host immune response to HCV infection results in viral 
clearance or immune pathology and chronic hepatitis (Cemy and Chisari 1999). 
The proportions o f CD56+T cells and Va24+NKT cells are decreased in the livers 
o f patients with chronic HCV infection compared with histologically normal 
donor livers (Deignan et al 2002). Hepatic y8 T cells have also been implicated 
in immunity against HCV The percentages o f V52/Vy9 TCR+ PBMCs are 
decreased in patients with chronic HCV (Par et al. 2002). It is not yet known if 
this decrease is reflected in the livers o f  these individuals.
1.5.9 Role of the DCs in immunity against HCV
DCs are highly specialised APCs that can activate restmg T cells and NK cells 
(Yu et al 2001, Nishioka et al 2001, Gerosa et al. 2002). MICA/B are induced on 
DCs by IFN-a stimulation and are capable o f activating NK cells However, in 
chronic HCV patients, IFN-a cannot induce DC-mediated NK cell activation 
(Jinushi et al 2003). This impairment might contribute to be the persistence o f  
this viral infection, and/or an insufficient responses to IFN-a therapy (Jinushi et 
al 2003). There is some evidence that DC can be infected by HCV. Furthermore, 
some expressed HCV genes may inhibit DC function, leading to reduction in IL- 
12 production. Changes in cytokine production by HCV infected DCs and 
macrophages lead to impaired effector function o f T cell activation (Bam et al
60
2001, Lee et al 2001, Sarobe et al 2002).
1.5.10 Role of NK cell in immunity against HCV
NK cells provide a critical first line o f  defense against viral infections both 
through their rapid and potent cytotoxic activity and the production of 
inflammatory cytokines. The importance o f NK cells in host defense to various 
viruses has been extensively studied using animal models where NK cell depletion 
or deficiency results in a significant increase m the sensitivity o f the animal to a 
number o f viruses (Biron et al. 1999). However, the role o f NK cells in HCV- 
related chronic liver disease is largely unknown. In the liver o f patients with 
chronic HCV infection, NK cells numbers were slightly reduced (Deignan et al
2002). The circulating number o f CD3CD8+ (NK cell subtype) have been shown 
to be decreased m peripheral blood o f chronic HCV patients (Par et al. 2002). The 
same study also found that NK cell cytotoxicity against K562 targets is impaired 
in chronic HCV infection. Although NK cell activity is enhanced by IFN-a, Par et 
al. (2002) found that NK cytotoxicity does not differ between responders and non­
responders to IFN-a treatment This suggests that NK activity does not help to 
predict the outcome o f IFN-a therapy. Increased NK activity was sustamed in 
subjects who were successfully treated with IFN-a and remained HCV negative, 
indicating that the HCV infection itself may be responsible for the altered NK cell 
function and clearance o f the virus may result in normalisation o f NK activity.
Corado et al. (1997) found that spontaneous NK cytotoxicity in blood of HCV 
patients was four-fold lower than in normal donors by using 51Cr-labeled K562 as 
target cells. They did not find any differences in cytotoxic activity between
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patients with HCV infection and healthy controls when they used U937 cells as 
target cells. In another study, Lirussi et al (2002) studied peripheral NK cell 
cytotoxicity using an ELISA based assay to assess o f apoptosis o f target K562 
cells. They found that NK cell cytotoxic activity was impaired in HCV patients. In 
contrast, Duesberg et al. (2001) mvestigated spontaneous and cytokine-induced 
(IL-2, IFN-y) cytotoxicity and ADCC in patients suffering from chronic HCV and 
healthy controls using a flow cytometric assay As target cells they used the 
colorectal tumour cell line HT29 and the lymphoma cell line Raji. They found no 
significant differences in spontaneous cytotoxicity and ADCC between patients 
and normal controls, even if isolated NK cells were studied. Preincubation and 
stimulation o f effector cells with cytokines increased both natural cytotoxicity and 
ADCC by 20-30% in all study groups. However, natural cytotoxicity and ADCC 
after stimulation did not differ between the patients with HCV and healthy 
controls.
Recently, the major HCV envelope protem E2 has been shown to inhibit NK cell 
production o f IFN-y and cytotoxic activity by cross-linking CD81 (Tseng and 
Klimpel 2002). The functional inhibition can be explained by the fact that CD81 
engagement blocks tyrosine phosphorylation o f important upstream and 
downstream signalling moieties induced by cross-linking CD 16. The direct 
inhibition o f NK cells via binding o f HCV-E2 to CD81 provides an “o ff’ signal 
for NK cell activation and efficiently blocks cytokine production, activation 
marker expression, cytotoxic granule release and proliferation (Crotta et al. 2002). 
This mechanism, which specifically down-regulates the NK cell response, may 
provide the virus with an efficient immune escape strategy capable o f limiting the
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antiviral activities o f NK cells early in the infections process (Crotta et al. 2002). 
In contrast, this interaction elicits an opposing effect in T cells, such that CD81 is 
co-stimulatory and enhances proliferation. Alterations in NK cell function could 
set up a situation where the virus might have an initial growth advantage that 
could then lead to the development o f a chronic and persistent infection that could 
not be completely cleared by T cell and B cell responses.
1.6 The aims of the project
The role o f NK cells in chronic HCV is controversial and poorly understood.
Some observations suggest that NK cells might be impaired in chronic HCV while 
others do not support this. To address this controversy, we determined the 
numbers, phenotypes and natural and LAK cytotoxic activities o f  circulating NK 
cells in large, well defined cohorts o f  patients with chronic HCV infection, 
patients who spontaneously resolved HCV infection and healthy donors.
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Chapter 2: Materials and methods
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Thirty-three patients with chronic HCV infection (twelve males, twenty-one 
females, median age 46, range 21 to 69 years) were studied. All patients were 
anti HCV antibody positive and HCV RNA positive. Of these patients, nineteen 
were infected with HCV genotype 3, thirteen were infected with genotype 1 and 
virological data was not available for one patient. Fifteen patients became infected 
with HCV as a result o f intravenous drug abuse (IVDA), twelve patients as a 
result o f  receiving anti-D immunoglobulin, four patients as a result o f  blood 
transfusion, one patient as a result o f sexual transmission and history was not 
available for the remaining patient. Thirteen patients had no liver cirrhosis as 
determined by a histological stage o f less than four using the modified histological 
activity index (HAI) scoring system (Ishak et al 1995). Three patients had HCV 
cirrhosis and histological data was not available for seventeen patients. None o f  
the HCV patients had been treated at the time o f study Twenty-two subjects 
(sixteen females, she males, median age 51, range 22 to 63 years) who 
spontaneously resolved HCV infection were also studied. All o f  these were 
consistently HCV RNA negative but HCV antibody positive. Of these, three 
individuals became infected with HCV as a result o f IVDA, eight individuals as a 
result o f receiving anti-D immunoglobulin, seven mdividuals as a result o f  blood 
transfusion and one patient as a result o f sexual transmission History was not 
available for three o f these subjects.
All patients were recruited at St.Vincent s University Hospital (SVUH), Dublin.
Twenty-six (fourteen females, twelve males) healthy volunteers served as
controls. For ethical reason none o f the controls were tested for HCV but these
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2.1 Subjects
individual had no history o f risk factors for HCV infection. Ethical approval for 
this study was obtained from the Research and Ethics committee, SVTJH and the 
Ethics Committee o f NUI Maynooth. Informed consent was obtained from all 
subjects.
2.2 Materials
2.2.1 General reagents
Bovine serum albumin (BSA), foetal calf serum (FCS), paraformaldehyde, 
phosphate buffered saline (PBS) and sodium azide were purchased from Sigma 
Chemie, Steinheim, Germany. Fungizone, Hank's balanced salts solution (HBSS), 
Hepes buffer, L-glutamine, penicillin-streptomycin and RPMI were purchased 
from Gibco-BRL, Paisley, UK. Acridine orange (AO), ethidium bromide (EB) and 
recombinant human IL-2 were purchased from Sigma Chemical Co. Ltd, Poole, 
UK Virkon was purchased from Antec International Limited, Suffolk, UK. Decon 
90 was purchased from Decon laboratories limited, Sussex, England. Optiphase 
cocktail was purchased from Wallac, Turku, Finland. Dimethylsulphoxide 
(DMSO) was purchased from BDH Laboratory Supplies, Poole, England. 
Ethylenediaminetetraacetic acid (EDTA) was purchased from Scharlau Chemie. 
Barcelona, Spain. Lymphoprep was purchased from Nycomed, Oslo, Norway.
5'Chromium was purchased from Radiochemicals Division, Irvine, California.
2.2.2 Antibodies
The monoclonal antibodies (mAbs), Anti-CD158a-congugated with fluorescein
isothiocyanate (FITC), Anti-CD161-FITC, Anti-CD16-FITC, Anti-CD4-FITC,
66
(
Anti-NKBl-FITC, Anti-CD56-congugated with phycoerythrin (PE), Anti-CD8- 
PE, Anti-CD3- congugated with peridin chlorophyll protein (PerCp) and Isotype 
control IgGl were purchased from BD Pharmingen, Oxford, UK.
2.2.3 Cell lines
K562 and Daudi were obtained from Derek Doherty, NUI Maynooth. Ireland
2.2.4 Plastic ware
96-well plates and cryovials were purchased from Nunc, Roskilde, Denmark. 
Tissue culture flasks, Micro fuge tubes, Transfer pipettes and Tips were purchased 
from Sarstedt, Numbrecht, Germany Wallac 96-well Isoplates were purchased 
from Wallac, Turku, Finland. Adhesive sheets was purchased from Sigma 
Chemie, Steinheim, Germany. Plate cassette was purchased from Perkm Elmer, 
USA.
2.3 Preparation of peripheral blood mononuclear cells (PBMCs)
Venous blood was taken into 0.5 % EDTA (1/10 dilution o f 5% EDTA stock) as 
anticoagulant, and diluted 1:1 with HBSS medium containing 1% FCS which was 
heat-inactivated for 30 min at 56°C. The diluted blood was carefully layered onto
7.5 ml Lymphoprep in a 30 ml Universal tube and centrifuged for 25 rrnn at 400 g 
(m a Centra CL3 centrifuge) with the brake off (minimum deceleration). The top 
(plasma) layer was removed by aspiration and discarded. The buffy coat (cloudy 
layer that sits on top o f  the Lymphoprep) plus the Lymphoprep layer were 
transferred to a clean Universal tube, ensuring that none o f the red cell pellet was
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taken. Buffy coat layers were resuspended in 20 ml HBSS containing 1% FCS, 
mixed and centrifuged for 5 mm at 800 g with the brake on.
The supernatant was discarded by tipping off once, and resuspending the pellet in 
a small volume (~1 ml or the amount o f liquid remaining) then vortexing. This 
was again resuspended in HBSS containing 1% FCS, mixed and centrifuged for 
10 min at 400 g with the brake on. The supernatant was again discarded and the 
pellet was resuspended in a small amount o f complete RPMI medium (RPMI1640 
containing 25mM HEPES, 2mM L-gluamine, 50 pg/ml streptomycin, 50U/ml 
penicillin and 10% heat-inactivated FCS).
2.4 Enumeration of PBMCs
A haemocytometer was used to enumerate PBMCs in suspension. The 
haemocytometer is a glass chamber, which holds a thin suspension o f blood cells 
that can be examined with a microscope. The improved Neubauer 
haemocytometer has a chamber that is 0.1 mm deep and is divided into a grid 
precisely 3mm x 3 mm, and subdivided into squares o f 0.25 mm x 0.25 mm and 
0.05 mm x 0.05 mm
Ten pi o f  cell suspension were added to 190 pi o f  a solution containing 16 pg/ml 
EB and 10 pg/ml AO in an Eppendorf tube and mixed well. Cells were counted on 
Neubauer haemocytometer slide, ensuring that the solution covered the entire 
surface o f  the counting chamber. Live cells only appearing in the two comers o f  
the grid 2 x (1.0 mm x 1.0 mm) were counted. Taking into account the 1/20 
dilution in EB/AO, the counts from two comers o f  the grid x 105 gives cell 
number/ml The total number o f PBMCs was calculated by multiplying the
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concentration in cell/ml by the number of ml o f  RPMI used to resuspend the cells
2.5 Cryopreservation of cells
For long-term storage, PBMCs were pelleted by centrifugation for 10 min at 800g, 
the supernatant was discarded, and the cells were resuspended in freezing mixture 
(90 % FCS containing 10 % DMSO, made up freshly, but in advance to allow it to 
cool as FCS and DMSO produce heat when mixed). Immediately cells were 
transferred to previously labelled cryovials and they were frozen at -80°C 
overnight. Next day, cryovials were transferred to liquid nitrogen.
Cryopreserved cells were recovered by thawing using warm water for few 
seconds. Cells were transfered immediately to universal tubes and RPMI was 
added dropwise. The cells were centrifuged at 400 g. The supemated was 
discarded and the cells were resuspended in complete RPMI.
2.6 Phenotypic analysis by flow cytometry
2.6.1 Brief background to flow cytometry
Flow cytometry employs instrumentation that scans single cells flowing past
excitation sources in a liquid medium. The technology is unique in its ability to
provide rapid, quantitative, multiparameter analyses on single livmg (or dead)
cells. Measurement o f visible and fluorescent light emission allows quantitation o f
antigenic, biochemical, and biophysical characteristics o f individual cells. Flow
cytometry can also separate distinct subpopulations o f  cells on the basis o f  these
measured characteristics, usually by electrostatic deflection. This separation
technology is called electronic cell sorting. A graphical representation o f up to six
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analytical measurements made on individual cells and can be used to quantity 
subpopulation o f cells.
Performing flow cytometry experiments generally involves three distinct, 
interdependent phases. First is the pre-flow cytometry phase, which involves 
reagent preparation, cell preparation, and staining o f  cells with fluorescent 
reagents. Second is the flow cytometry phase, which mvolves processing the 
stained cells using flow cytometry instrumentation and collecting data for one, or 
more measurements (parameters) made on each individual cell Finally, the 
analysis phase involves analysing the collected data (Colican et al. 2002).
The sample is forced from a container through sample tubing to enter a nozzle. 
Here the sample stream meets with the sheath fluid; the sheath fluid surrounds the 
sample stream keeping it straight and in focus. The stream passes at nght angles to 
an argon laser (488 nm). Transmitted and reflected light impinges on 
photodetetors via a series o f strategically placed dichroic and band pass filters. 
Photodetectors and photomultiplier tubes amplify and convert the analogue signal 
to a digital format so that a computer can process the information. One detector is 
placed directly in the path o f the laser and detects low angle light scatter or 
forward angle scatter (FSC) and relates to cell size. A photodetector placed 
perpendicular to the laser detects 90° or side angle light scatter (SSC), and relates 
to the granularity o f the cell. Using a combination o f FSC and SSC allows us to 
distinguish cell populations based on their morphological properties and larger 
more granular cells such as macrophages are easily distinguished from smaller 
less granular cells such as lymphocytes (Pillemer 1990). Photodetectors that
measure fluorescence at four different wavelengths can then distinguish 
phenotypic variants o f cells stained with mAb conjugated with fluorochromes. In 
the present study phenotypic analysis o f  PBMCs was performed by three color 
mAb staining and flow cytometry using a FACSCalibur (Becton Dickinson) and 
analysis-using cell Quest software (Becton Dickinson).
2.6.2 M onoclonal antibody (mAb) staining o f PBM Cs
1.2 x 106 cells were resuspended in 600 pi PBA buffer which is composed o f 600 
ml o f  PBS containing 1 % BSA and 0.02 % sodium azide. 100 pi o f cells (0.2 x 
105 cells) m PBA buffer were transferred to each o f 6 labelled FACS tubes. 5 pi o f  
each fluorochrome-conjugated mAb were added to the cells. The mAb and 
appropriate fluorescence-labelled isotype-matched control antibodies, used to 
correct for any background staining, are shown in Table 2. All mAbs were directly 
conjugated with fluorochromes. Cells were then vortexed and incubated for 15 
min at room temperature in the dark (covered in tin foil) Two millilitres o f PBA 
buffer were added, vortexed and centrifuged for 5 min at 800 g force.
Supernatants were discarded and pellet were resuspended in -0.5 ml PBA buffer.
I
Table 2. Monoclonal antibodies used for staining o f  PBMCs.
Tubes PerCP-labelled mAb PE- labelled mAb FITC-labelled mAb
CONTROL
2
3
4
5
6
MOUSE IgG
CD3
CD3
CD3
CD3
CD3
MOUSE IgG
CD56
CD56
CD56
CD56
CD8
MOUSE IgG
CD16
CD161
KIR2DL1
KIR3DL1/S1
CD4
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2.6.3 Flow cytometric acquisition and analysis of data
Freshly isolated PBMCs were stained with mAbs as described in section 2.7.2. 
With the flow cytometer in ‘setup’ mode, cells were run through the cytometer 
and the detectors and parameters were set so that lymphocytes could be 
distingushed by virtue o f their FSC and SSC properties, as shown in Figure 12A. 
The detectors and parameters were then set so that gated lymphocytes that were 
stained with isotype-matched control mAbs located to the bottom left-hand 
quadrant o f dot plots o f fluorescence-1 (FL1) vs FL2, FL1 vs FL3, and FL2- FL3 
(Fig. 12B). Cells stained with mAbs specific for CD3, CD4 and CD8 (see Table 2) 
were then run through the cytometer and compensations were set to eliminate 
fluorescence overlap o f two fluorochromes (Fig. 12C). The cytometer was then set 
to ‘run’ and data for all tubes were acquired and saved to disk.
Analysis o f data involved the enumeration o f monocytes, lymphocytes, T cells 
defined by the expression o f CD3, and NK cells defined by CD3'CD56+ or CD3' 
CD161+ phenotypes. The expression o f  other NK receptors (NKRs) by non-T 
(CD3‘) and T (CD3*) lymphocytes was further quantified.
2.7 Cell culture
Experimentation with human PBMCs poses safety problems associated with the 
risk o f infection with human disease agents For this reason, all procedures were 
performed according to the guidelines set out for working in the Lymphocyte 
Biology Laboratory at NUI Maynooth These include wiping with 70% alcohol 
before and after the work, use o f laboratory coats and safety gloves, hand washing
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Fig. 12: Setting up the flow cytometer for 3-colour analysis o f lymphocyte. (A) 
Flow cytometric dot plot showing forward scatter and side scatter properties 
of human peripheral blood monocytes and lymphocytes. (B) The level of 
staining seen with isotype matched control antibodies was used to set the 
fluoroscent detectors to the appropriate levels. (C) Cells stained with mAbs 
specific for CD3, CD4 and CD8 to set the compensations.
and daily decontamination o f work surfaces. Cells were processed in a laminar
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airflow cabinet. All the liquid wastes were discarded in Virkon at a concentration 
o f 10mg/L o f water. Solid waste (tips, transfer pipettes, gloves, 96 well plates, 
tubes and flasks) were autoclaved before discarding.
PBMCs were cultured for 1-2 days in complete RPMI medium in 75 cm2 tissue 
culture flasks with loose lids in a Thermoforma CO2 incubator at 37 °C and 5% 
CO2. In some cultures recombmant human IL-2 was added at a concentration of  
25 ng/ml.
K562 and Daudi cells were kept in continuous culture at 37 °C and 5% CO2 in 
complete RPMI medium. Culture were diluted with medium every 3-4 days to 
maintain cells at densities o f  <0.3 x 106 cells/ml.
2.8 Analysis of cytotoxicity
The human chronic myeloid leukemia derived cell line K562 is often used as a 
system to address scientific problems o f hematological relevance. In the present 
study K562 cells were chosen because they are sensitive cytotoxicity by NK cells. 
Daudi cells, a human lymphoblastoid line, was also used as a target for 
cytotoxicity assays because these cells are resistant to natural cytotoxicity by NK  
cells, but NK cells can be induced to kill Daudi cells by activation with cytokines.
It is important that the target cells are viable and healthy on the day o f cytotoxicity 
assays. This can be encouraged by feeding them with RPMI medium the previous 
day. All effector cells were cryopreserved before use so that they were treated 
under similar situation. An internal control containing frozen PBMCs from the 
same healthy individual was used in all experments to monitor day-to-day
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variation in cytotoxic activity.
To avoid the risks associated with the use o f radioactive materials, many safety 
procedures were taken in radioactive suite. Laboratory coat, lead jacket, 
radioactive dosimeter and two pairs o f disposable gloves were worn at all the 
tunes. All work was carried out behind the lead-acrylic screen designated for 51Cr 
use. All containers o f  radioactive materials were clearly labelled and all 
contaminated glassware were soaked in appropriate detergent (Decon 90%) and 
washed in running water. Contamination checks were carried out with the Mini­
monitor and by taking wipes for counting in the liquid scintillation counter. Wipes 
were taken with a cotton bud wetted with 2% Decon, and placed in a liquid 
scintillation vial with scintillation fluid and counted. Any areas, which recorded 
above background, were cleaned thoroughly with detergent and water. Use and 
disposal forms were filled with details o f amounts o f waste generated. In addition, 
the suite user’s logbook was filled in every time the radiation suite is used.
All solid waste was bagged with a tag including name, isotope and date. This was 
stored in large lead box in the radiation suite until no radiation could be detected 
usmg the Mmi-monitor. It could then be disposed o f with the ordinary waste. 
Liquid waste was collected m labelled Winchester waste bottles containing
radioactive tape and stored underneath the fume hood until the activity is
/
undetectable.
Target cells were labelled with 50 pCi 51chromium (per ~0 5xl06 cells). They 
were resuspended in 1 ml complete RPMI medium then incubated at 37 °C in a 
hybridisation oven in the radioactive suite for 2 hours in a lead box. The cells
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were then pelleted by centrifugation at 110 g for 5 min. with the brake off The 
supernatant was removed using a wide-gauge pastette and discarding in the liquid 
waste container. To avoid cell damage that might lead to non-specific leakage o f  
51Cr, cell pellets were not resuspended. 15 ml complete RPMI were added to and 
cells which were pelleted as above. This wash step was repeated three more times. 
Only after the final wash, cells were resuspended, this tune in 1 ml complete 
RPMI
The densities o f labelled cells were counted in a counting chamber designated for 
radioactive use only. Complete RPMI was added to brmg the cell density to 
13,333 or 26,666 cells/ml and 75pl o f cells (1000 or 2000) were added to each 
well o f a sufficient number o f 96-well plates. The actual number o f targets used 
per well is not critical but it is important that the same number o f targets is placed 
in each well. Triplicate samples were analysed in all cases.
Effector cells were prepared by culturing PBMCs in the absence or presence of  
IL-2 as described in section 2 8. The cells were then washed and an aliquot stained 
m EB/AO for a viable cell count. Complete RPMI was added to bring the cell 
density so that 75 pi can be added to each well to get effector/target (E/T) ratios o f  
5/1, 50/1 and 100/1 In some case insufficient cells were available so E/T ratios o f  
5/1, 10/1, 50/1 were used. 75 pi effectors were aliquoted per well onto the 51Cr- 
labelled targets. As controls for each target cell, triplicate samples containing 
equal numbers o f target cells were included. In the first triplicate sample 75 pi o f  
complete RPMI was added instead o f effector cells to determine spontaneous 51Cr 
release. In the second, 75 pi o f 0.1 % triton X -100 was added to determine 
maximum release.
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Cells were concentrated at the bottoms o f the wells by centrifugation o f  the plates 
at 110 g with the brake off and allowing them to cruise back to zero Cells were 
then incubated for 2 hours at 37 °C in lead box in a hybridisation oven to allow 
for target cell lysis to occur. After 2 hours, cells were again pelleted in the wells 
by centrifugation o f the 96-well plates at 110 g for 5 min. with the brake off. 150 
pi Optiphase supercocktail and 25 pi cell supernatant were added to each well in a 
wallac 96-well isoplate. Isoplates were covered with adhesive sheets and gently 
mixed for 15 minutes in hybridisation oven. The Isoplates were then attached to a 
Perkm Elmer plate cassette and placed in the Wallac Microbeta plate counter, 
which automatically counts the amounts o f 51 Cr in the supematents o f each w e ll.
Specific lysis was calculated as (cpm o f sample- cpm o f spontaneous 
release)/(cpm o f maximum release- cpm of spontaneous release ) xlOO %.
2.9 Statistical analysis
All data on the patients and controls were entered into a computerised data base 
using Microsoft Excel. Minitab was used to analyse data. Cell numbers were 
expressed as median percentages ± standard errors. Cytolytic activities were 
expressed as means o f triplicate samples and as means o f mean specific activities 
within subject populations. The Mann Whitny U test for non-parametric data was 
used to compare median cell numbers and mean cytolytic activities. P values o f  
<0.05 were taken as significant. Spearman Rank analysis was used for correlation 
studies.
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Chapter 3: Results
3.1 A variety o f NKRs are expressed by human T cells and non-T  
lymphocytes
PBMCs from 33 patients with chronic HCV disease, 22 patients who 
spontaneously cleared HCV infection (HCV resolvers) and 26 healthy control 
individuals were stained with mAbs specific for CD3 and either CD16, CD56, 
CD161, KIR2DL1 or KIR3DL1/S1 and analysed by flow cytometry. 
Representative dot plots obtained are shown in Figure 13. The results indicate that 
different NKRs are differentially expressed by T cells and non-T cells and that 
multiple NK cells subsets (CD3' NKR+) and NKR+ T cell subsets (CD3+ NKR+) 
can be defined phenotypically.
3.2 Circulating NK cell numbers are depleted in patients with chronic HCV  
disease
The percentages o f  lymphocytes expressing CD3"CD56+ phenotypes were 
significantly reduced in patients with chronic HCV disease compared to controls 
(median= 3.4 + 0.8 vs 13.7 ± 1.3, PO.OOl, Fig 14A). NK cells defined by the 
CD3'CD161+ phenotype were also decreased in chronic HCV group compared to 
controls (median=6.6 vs 15.5; p<0.001, Fig. 14B). The percentages o f  
lymphocytes bearing CD3'CD56+ and CD3'CD161+ phenotypes were also lower 
in HCV resolvers group compared to controls (median=6.1 vs 13.7; p=0.0002 for 
CD56, 6.7 vs 15.5; p=0.0001 for CD161), but no significant differences were seen 
in the frequencies o f  expression o f CD3 'CD56+ and CD3 'CD161+ phenotypes 
between chronic HCV and HCV resolver groups.
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Fig.13: Flow cytometric analysis of CD16, CD56, CD161, KIR2DL1 and 
KIR3DL1/S1 by T cells (CD3+) and non-T lymphocytes (CD3 ) in the preipheral 
blood of a healthy individual after gating on lymphocytes.
The number in the quadrants indicate the percentages of lymphocytes that are 
negative (bottom left), single positive (upper left and lower right) and double 
positive (upper right) for each pair of receptors.
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Fig. 14: Circulating NK cell numbers are depleted in patients with chronic 
HCV disease. Median percentage of total lymphocytes expressing CD3 
CD56+ (A) and CD3CD161+ (B) phenotypes in 33 patients with chronic 
HCV disease, 22 HCV resolvers and 26 healthy controls. Error bars show 
stander errors.
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3.3 Circulating NKR+ T cell numbers are depleted in patients with chronic 
HCV disease
The proportion o f lymphocytes that coexpress CD3 and either CD56 or CD161 
were also found to be depleted in patients with chronic HCV disease. Figure 15A 
shows that CD3+CD56+ cells accounted for median o f 1.3% o f lymphocytes in 
patients with chronic HCV disease, compared with 3.7% in healthy controls 
(P=0.0001) and 1.5% o f HCV resolvers (P not significant when compared with 
chronic HCV, but there was a significantly decreased when compared to healthy 
control; p<0.001). Similarly CD3+CD161+ lymphocytes were depleted in patients 
with chronic HCV disease (5.6%) compared with controls (11.5%, P<0.001; Fig. 
15B). Numbers o f  CD3+CD161+ lymphocytes were also decreased in HCV 
resolvers (5.3%) compared to controls (p<0.001), but these was not significantly 
different when comparing to the chronic HCV group.
3.4 NK cell phenotypes in patients and controls
Smce different NKRs are differentially expressed by NK cells (Fig. 13), the 
expression o f CD56, CD161, CD16, KIR2DL1 and KIR3DL1/S1 by circulating 
CD3‘ negative lymphocytes in chronically HCV-infected patients (n=33), HCV 
resolvers (0=22) and healthy controls (n=26) were compared. Figure 16 shows 
that the frequency o f  expression o f  CD161 and CD 16 by non-T cells is reduced in 
patients with chronic HCV infection compared with controls (medians = 17.3% 
vs 32.7 for CD161; p=0.0004 and 13.9% vs 27.1% for CD16; p=0.038; Fig 16). 
Expression o f CD 161 in HCV resolvers was significantly lower when compared 
to healthy controls (medians=21.1 vs 32.7, p=0.0036), but there were not any
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Fig.15: Circulating NKR+ T cells are depleted in chronic HCV disease. 
Median percentage of total lymphocytes expressing CD3+CD56+ (A) and 
CD3+CD161+ (B) phenotypes in 33 patients with chronic HCV disease, 
22 HCV resolvers and 26 healthy controls. Erorr bars show standard 
errors.
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Fig. 16: Expression of CD56, CD16, CD161, KIR2DL1 and KIR3DL1/S1 
by circulating CD3‘ lymphocytes in healthy controls (n=26), patients with 
chronic HCV disease (n=33) and HCV resolvers (n=22). Data show 
median percentages and standard errors.
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differences in expression o f CD 16 from both groups Expression o f CD 16 by NK 
cells was slightly lower in chronic HCV compared to HCV resolvers, but this was 
not significant. KIR2DL1 was more frequently expressed by NK cells in patients 
with chronic HCV infection (4.6%) and in HCV resolvers (6.9%) compared to 
controls (2.2%, p=0.0009 and 0.0005 respectively; Fig 16). The frequencies o f 
non-T cells expressing CD56 and KIR3DL1/S1 were similar in all subject groups 
(Fig. 16). These results indicate that, while overall NK cell numbers are depleted 
in patients with chrome HCV disease, changes m the distributions o f NK  
phenotypic variants o f NK cells are also seen.
3.5 NKR+ T cell phenotypes in patients and controls
The expression o f CD56, CD161, CD16, KIR2DL1, and KIR3DL1/S1 by T 
lymphocytes in chronically infected patients, HCV resolvers and healthy controls 
groups was also compared. Figure 17 shows that the frequencies o f  T cells that 
express CD56 and CD 161 were decreased in patients with chronic HCV disease 
compared to controls (3.8% vs 6.7% for CD56; p=0.0007; 9.6% vs 13.1% for 
CD161; p=0.0047). They were also decreased in HCV resolvers group compared 
to controls (3.8 vs 6.7; p=0.0076 for CD56, 8.3 vs 13.1; p=0.0015 for CD161), but 
were similar in the HCV resolvers and chronic HCV groups.
The frequences o f T cells expressing KIR2DL1 were increased in patients with 
chronic HCV disease compared to healthy controls (0.43% vs 0.21%; p=0.0009, 
Fig 17). The frequences o f T cells expressing KIR2DL1 were similar m HCV 
resolvers (0.33) and chronic HCV. CD16 and KIR3DL1/S1 were found on similar 
proportion o f T cells in all subject groups (Fig. 17).
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Fig. 17: Expression of CD56, CD16, CD161, KIR2DL1 and KIR3DL1/S1 by 
circulating CD3+ lymphocytes in healthy controls (n=26), patients with 
chronic HCV disease (n=33) and HCV resolvers (n=22). Data show median 
percentages and standard errors.
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3.6 Natural cytotoxicity by PBMCs is impaired in patients with chronic HCV 
infection
NK cells are capable of killing a range of tumour target cells lines. We compared 
the natural cytotoxic activities of PBMCs from 33 patients with chronic HCV 
disease, 22 HCV resolvers and 26 healthy controls against K562 (Fig. 18) and 
Daudi (Fig. 19) targets. In these experiments, an internal PBMCs standard, which 
had been cryopreserved in a similar fashion to the test effector PBMCs was 
included to monitor for day-to-day variations in background 51chromium release. 
Figure 18A shows that the percent specific lysis of K562 cells was higher at E/T 
ratios of 50/1 compared with 5/1, but was consistently lower at E/T ratios of 
100/1, suggesting the presence of an inhibitor that is active at E/T ratios of 100/1. 
Comparsion of the specific lysis obtained with PBMCs from the three subject 
groups at E/T ratios of 50:1 (Fig. 18B) showed significantly reduced natural 
cytotoxicity in the chronically infected patients (1.8%) compared to HCV 
resolvers (7.4%; p=0.0012) and controls (10.2%; p<0.001). There was no 
significant difference in comparing HCV resolvers group to the controls. When 
Daudi was used as the target cell line in similar experiments, no natural 
cytotoxicity was observed at all E/T ratios tested m the HCV resolvers and 
chronic HCV groups. However, natural cytotoxicity against Daudi cells was 
detected in the PBMCs of 8 out of 26 healthy volunteers giving a mean specific 
activity of 3.3 at an E/T ratio of 50:1 (Fig. 19). No correlation was seen between 
NK cell phenotype and natural cytotoxicity against Daudi cells as shown for 
CD 16 in figure 20.
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Fig. 18: Natural cytotoxicity against K562 targets is impaired in chronic 
HCV infection. A, mean cytolytic activities of total PBMCs from 33 
patients with chronic HCV disease, 22 HCV resolvers and 26 controls 
against K562 targets at effector/target (E/T) ratios of 5:1,50:1 and 100:1. 
B, comparison of mean specific lysis at E/T ratios of 50:1 between subject 
groups.
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Fig. 19: Natural cytotoxicity against Daudi targets is impaired in chronic 
HCV infection. A,mean cytolytic activities of total PBMCs from 33 
patients with chronic HCV disease,22 HCV resolvers and 26 controls 
against Daudi targets at effector/target (E/T) ratios of 5:1,50:1 and 
100:1. B, comparison of mean specific lysis at E/T ratios of 50:1 between 
subject groups.
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% of NK cells expressing CD16
Fig. 20: Natural cytotoxicity of Daudi targets does not correlate with NK 
cell phenotype. The expression of CD16 by NK cells in 26 healthy donors is 
plotted against % specific lysis of Daudi cells.
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3.7 Lymphokine-activated killing (LAK) by PBMCs is impaired in patients 
with chronic HCV infection
Cytotoxic activity of PBMCs from chronically HCV-infected patients, HCV 
resolvers and healthy controls against K562 and Daudi targets was also tested 
after incubating the PBMCs effectors for 1-2 days with 25 ng/ml IL-2. IL-2 
activation led to increased cytolysis against both targets. Figure 21A and 22A 
show the LAK activity of PBMCs against K562 and Daudi at E/T ratios of 5/1, 
50/1 and 100/1. Comparing groups of subjects at E/T ratios of 50:1, LAK activity 
against K562 was significantly reduced in chronic HCV disease (2.5%) compared 
with HCV resolvers (7.55%; p=0.0001) and controls (12.6%; p<0.001, Fig. 21B). 
There was no significant difference in comparing HCV resolvers group with the 
healthy controls. LAK activity agamst Daudi targets was similarly reduced in 
chronically-infected patients (0%) compared with HCV resolvers (2.5%, p<0.001) 
and controls (8.1%; p<0.001; Fig.22 B). A significant difference was also seen 
when HCV resolvers and controls were compared (p=0.0074).
3.8 Impaired cytotoxic activity of PBMCs in chronic HCV infection is not 
solely due to decreased NK cell numbers or NKR+ T cells numbers
The present study has demonstrated that NK and NKR+ T cell numbers are 
depleted in chrome HCV disease and that natural cytotoxicity and LAK activity 
are also impaired. To determine if impairment in cytotoxicity is merely due to low 
NK numbers we performed Rank Spearman analysis of NK cell numbers and % 
specific lysis at E/T of 50/1 (Fig. 23). The results indicate that impaired 
cytotoxicity in chronic HCV infection is not solely due to the decrease in NK cell
numbers.This impairment in cytotoxic function is also not solely due to decreased 
numbers of total lymphocytes (both NK cells and T cells) expressing CD56 (Fig. 
24).
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Fig. 21: Lymphokine activated killing of K562 target is impaired in 
chronic HCV disease. A, mean cytolytic activities of total PBMCs 
from 33 patients with chronic HCV disease, 22 HCV resolvers and 
26 controls against K562 targets at effector/target (E/T) ratios of 5:1, 
50:1 and 100:1. B, comparison of mean specific lysis at E/T ratios of 
50:1 between subject groups.
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Fig. 22: Lymphokine activated killing of Daudi target is impaired in 
chronic HCV disease. A, mean cytolytic activities of total PBMCs 
from 33 patients with chronic HCV disease, 22 HCV resolvers and 
26 controls against Daudi targets at effector/target (E/T) ratios of 
5:1, 50:1 and 100:1. B, comparison of mean specific lysis at E/T 
ratios of 50:1 between subject groups.
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Fig. 23: Reduced natural cytotoxicity and LAK activity in chronic HCV 
disease is not solely due to depletion of NK cell numbers. Plot of median 
NK number (% of lymphocytes) against mean natural cytotoxicity (A) 
and LAK activity (B) at E/T ratios of 50/1 for all individuals.
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Fig. 24: Reduced natural cytotoxicity and LAK activity in chronic HCV 
disease is not solely due to depletions of total NK and NKR+ T cell 
numbers. Plot of median CD56+ cell (NK and T cell) number (% of 
lymphocytes) against mean natural cytotoxicity (A) and LAK activity (B) 
at E/T ratios of 50/1 for all individuals.
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Chapter4: Discussion
NK cells are thought to play an important role m immunity against viruses. They 
can recognise virus infected cells and release IFN-y, which not only inhibits virus 
replication but also can activate other cells mvolved in cell-mediated immunity 
(Biron et al 1999, Trinchieri 1995). NK cells also mediate cytolysis, which plays 
an important role in host antiviral defence mechanisms (see Chapter 1).
NK cell deficiency states are associated with a range of diseases and
susceptibilities to infections. Current evidence suggests that a decreased NK cell
number or cytotoxic activity is often associated with the development and/or
progression of cancer, acute or chronic viral infection, autoimmune diseases,
immune deficiency syndromes and psychiatric illness (Whiteside and Herberman
1994, Shibatomi et al 2001, Wilson et al 1994, Jo vie et al 2001). Low NK cell
function has been linked to increased susceptibility to Epstein-Barr virus, human
cytomegalovirus, and human immune deficiency virus (HIV) (Ching and Lopez
1979, Mermo et al 1986, Biron et al 1999). However, the role of NK cells m
immunity against HCV has not been fully explored. NK cell function has been
shown to be significantly lower in patients with chronic HCV infection, compared
with healthy controls (Lirussi et al 2002, Corado et al 1997, Pare/ al 2002),
however this observation has not been confirmed in another study (Duesberg et al
2001). In the present study, we evaluated the NK cell numbers, phenotypes,
natural cytotoxic activities and LAK activities in PBMCs of HCV infected
patients, HCV resolvers and healthy controls groups. Our results show that a
variety of NKRs are expressed by human T cells and non-T lymphocytes. Both
NK cells and NKR+ T cells numbers are depleted in the blood of chrome HCV
patients. In addition to decreases in numbers of these cells, we found that NK cells
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in patients with chronic HCV infection have altered phenotypes. Expression of 
CD 161 and CD 16 by NK cells was found less frequently in patients with chronic 
HCV compared to healthy controls. In contrast, KIR2DL1 was more frequently 
expressed by NK cells in chronic HCV patients. Expression of KIR3DLI/S1 and 
CD56 was similar m all study groups. The frequencies of T cells expressing 
CD161 and CD56 were also decreased in chronic HCV patients compared to 
controls. In contrast the frequencies of T cells expressing KIR3DL1/S1 and CD 16 
were found to be similar in all study groups and the frequencies of T cells 
expressing KIR2DL1 were increased m chronic HCV patients compared to 
controls.
We also found that natural cytotoxicity and LAK activity by PBMCs against K562 
and Daudi target cells are impaired in patients with chronic HCV infection 
compared to HCV resolvers and controls This impaired activity is not solely due 
to the decreases in NK cell numbers or NKR+ T cells numbers.
Our results are different from those of Duesberg et al (2001) who found that 
natural cytotoxicity, LAK activity and ADCC were not impaired m a cohort of 29 
patients with chrome HCV disease compared to controls. These differences may 
relate to differences in target cells used (HT 29 and Raji) or methodologies (we 
used the chromium release assay but Duesberg and coworkers used a flow 
cytometric assay for the assessment of cytotoxicity). Alternatively the different 
results may be due to differences in the patients. While Duesberg and coworkers 
studied patients mfected with genotypes la, lb, 2a/2c and 3a, we studied patients 
infected with genotypes 1 and 3.
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We were surprised to find that the frequencies of circulating NK cells and NKR+
T cells were significantly lower in the blood of patients who spontaneously 
resolved HCV compared to controls. This suggests that the virus may be 
responsible for depleting these cell numbers and that they do not expand after 
elimination of the virus, rather than reduced NK and NKR+ T cell numbers 
predisposing individuals to chronic HCV infection. We can not exclude the 
possibility that lower NK and NKR+ T cell counts in the chronic HCV and HCV 
resolver groups are due to differences in cell preparation and storage, since 
PBMCs from HCV patients and resolvers were prepared at St. Vincent’s 
University Hospital while PBMCs from controls were prepared at NUI Maynooth. 
However, identical methods and reagents were used at both centres and NK cell 
and NKR+ T cell numbers were similar in PBMCs prepared from healthy control 
subjects prepared at the two laboratories (data not shown).
The reduction in cytotoxic activity m patients with chronic HCV infection may be 
a factor that underlies susceptibility to chronic HCV disease, the result of viral 
infection of NK cells and NKR+ T cells, or the induction of factors that might alter 
NK cell function. Impaired NK cytotoxic activity in chronic HCV groups and 
HCV resolvers may be attributed to the effect of suppressive cells and/or factors 
present in PBMCs of infected patients. Corado et al (1997) used PBMCs 
depleted of monocytes and B cells and purified NK cells as effectors in 
cytotoxicity assays.
They found that in spite of the depletion of monocytes and B cells, NK cytotoxic 
activity was still significantly lower compared with that of healthy controls.
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Therefore, monocytes and B cells or their soluble factors do not seem to be 
implicated in the reduced NK activity. Also they found that short term in vitro 
stimulation with IL-2 partially restores NK cell cytotoxic activity in chronic HCV. 
HCV might impair NK cell activity by reducing the amount of IL-2 produced, a 
cytokine that stimulates NK cell response (Corado et al 1997).
The possibility that HCV might alter NK cell function has also been suggested in 
experiments in which PBMCs from healthy individuals were exposed to virus- 
containing serum obtained from HCV infected individuals. This resulted in the 
inhibition of NK mediated cytotoxicity (Corado et al 1997). The same group 
found that impairment of NK cytotoxic activity was specific to HCV infection 
because the cytotoxic function of PBMCs incubated with serum from patients 
with hepatitis A virus (HAV) or hepatitis B virus (HBV) infections or 
autoimmune hepatitis was comparable to that of PBMCs incubated with serum 
from healthy controls.
It has been shown that the major HCV envelope protein E2 can inhibit, via cross 
linking CD81, NK cell production of IFN-y, non-MHC restricted cytotoxic 
activity, activation marker expression, cytotoxic granule release and proliferation 
(Tseng and Klimpel 2002, Crotta et al. 2001). Thus, cross linking of CD81 on NK 
cells results m inhibition of NK cell function. In contrast, cross linking of CD81 
on T cells or B cells result in costimulation. These different outcomes of cross 
linking CD81 on NK cells and other cells due to the activation of distinct 
signalling pathways (Crotta et al 2001). This finding provides a mechanism by 
which HCV might interfere with NK responses at the early stages of infection 
resulting in the generation of a persistent infection.
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HCV may also impair NK fonctions at the level of DC activation. DCs augment 
effector fonctions of NK cells, but the mechanisms are not folly understood. 
Jinushi et al (2003) show that human monocyte derived DCs enhance IFN-y 
production, CD69 expression, and K562 cytolytic ability of NK cells when DCs 
are prestimulated with various maturation stimuli such as IFN-a or 
lipopolysaccharide (LPS). They found that NK cell activation mediated by LPS- 
stimulated DCs was dependent on IL-2, but that IFN-a stimulated DC mediated 
activation was not. IFN-a was found to induce the expression of the MHC class I 
related chains, MICA and MICB, which are ligands for the stimulatory receptor 
NKG2D found on NK cells. IFN-a-mediated activation of NK cells was 
dependent on the MICA/B-NKG2D interaction and could be blocked using mAbs 
against MICA/B or by inhibition of direct cell to cell contact using transwell plate 
systems. DCs recovered from chronic HCV infected patients showed defects in 
the mduction of MICA/B and impaired ability to activate NK cells in response to 
IFN-a stimulation. These findings suggest that MICA/B induction on DCs may be 
one of the mechanisms by which IFN-a activates NK cells; this impairment might 
affect IFN-a responsiveness in HCV infection.
The results of the present study could have important implications for our 
understanding of host immune response to HCV. Depleted NK fonction and 
insufficient production of IFN-y by NK cells could alter the development of Thl 
responses and favor the development of enhanced Th2 responses Interestingly, an 
imbalance between Thl versus Th2 responses has recently been described in 
chronic HCV infected individuals (Sarih et al 2000, Valiante et al 2000). Sarih et
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al (2000) investigated the levels of Thl cytokines (IL-2, IL-12, IFN-y) and Th2 
cytokines (IL-10, IL-4) and their response in peripheral blood from HCV infected 
patients. They found that IFN-y and IL-12 levels were lower in HCV infected 
subjects as compared to controls They also found no difference in IL-2 and IL-10 
production. In contrast, Deignan et a l (2002) found that IFN-y level was 
significantly increased in liver of patients with HCV infection. Golden-Mason et 
al (2003) also found that IL-18, IFN-y and IL-10 levels were significantly 
increased in the livers of patients with HCV infection.
There is evidence that the NK cell mediated and CTL mediated cytotoxic systems 
regulate the functions of each other (Kos and Edgar 1996). The existence of a 
dynamic balance between NK cell and CTL systems may be essential to host 
defenses. If CTL precursors are not able to recognize target cells due to their 
expression of suboptimal levels of MHC class I molecules, NK cells can provide a 
protective cytotoxic backup system, although of limited efficiency. However, if 
CTL precursors efficiently recognize their targets and undergo activation, NK 
cells are signalled to limit their activity, allowing the CTLs to be dominant cells 
mediated cytotoxic system fighting an infection. Decreased NK function in HCV 
patients may impact on these interactions leading to dysfunction of the immune 
system.
Future studies using hepatic NK cells from large numbers of patients are required
to determine whether the observations of the present study are also found in the
liver. These studies should include the use of purified NK cells and NKR+ T cells
so that the contributions of other cell types to the impairment in cytotoxicity in
HCV disease can be assessed. Cytotoxicity agamst broader range of target cells
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lines should also be assessed. Future studies on cytokine production by NK and 
NKR+ T cells from controls and patients with chronic HCV infection may also 
lead to the identification of mechanism of HCV persistence. An analysis of the 
effects of culturing NK cells from patients with chrome HCV infection and HCV 
resolvers with IFN-a may lead to the identification of mechanism by which the 
^response to IFN-a is defective in some individuals Finally, a study of changes in 
NK activity and/or numbers during the course of disease or response to treatment 
may provide further information on this issue. An improved understanding of NK 
and NKR+ T cell may ultimately lead to the identification of cellular or molecular 
targets for therapeutic intervention for HCV disease.
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